СПОСОБ ПОЛУЧЕНИЯ УСТРОЙСТВ ДЛЯ ОСТЕОСИНТЕЗА, УСТРОЙСТВА И ИМПЛАНТАТЫ ДЛЯ ОСТЕОСИНТЕЗА, ИЗГОТОВЛЕННЫЕ ИЗ ПОЛУСИНТЕТИЧЕСКОГО ГИБРИДНОГО МАТЕРИАЛА, ПОЛУЧЕННОГО СТРУКТУРНОЙ МОДИФИКАЦИЕЙ КОМПОНЕНТОВ ПРИРОДНОГО МОРСКОГО БИОМАТЕРИАЛА

Изобретение относится к фармацевтической промышленности, а именно к способу получения полусинтетического гибридного материала из природного гибридного биоматериала. Способ получения полусинтетического природного гибридного биоматериала, который представляет собой перламутровый арагонитовый слой двустворчатых моллюсков, выбранный из группы, состоящей из Pinctada maxima, Pinctada margaritifera, Tridacnae maxima, Tridacnae gigas и других видов Pinctada, который содержит неорганическую фракцию и органическую фракцию, причем способ включает стадию модификации рН и стадию перекрестного сшивания органической фракции указанного природного гибридного биоматериала, в котором стадия модификации рН осуществляется путем погружения природного гибридного биоматериала в ванну с микробиологически контролируемой водопроводной водой, доведенной до температуры кипения до получения искомого рН, стадия перекрестного сшивания осуществляется с помощью перекрестно-сшивающего агента и/или физических агентов, при ...

СПОСОБЫ РЕЦЕЛЛЮЛЯРИЗАЦИИ ТКАНИ ИЛИ ОРГАНА ДЛЯ УЛУЧШЕНИЯ ПРИЖИВЛЕНИЯ ТРАНСПЛАНТАТА

Изобретение относится к медицине. Описан способ рецеллюляризации ex vivo матрикса ткани или органа, включающий: a) предоставление децеллюляризованного матрикса органа млекопитающего или васкуляризованной ткани, где матрикс включает интактную капсулу органа, содержит сосудистую систему и где, когда жидкость вводят в одной точке входа указанной сосудистой системы указанного децеллюляризованного матрикса, указанная жидкость выходит другим путем; и b) реэндотелизацию матрикса указанных ткани или органа путем перфузирования, в антеградном и ретроградном направлениях, указанной децеллюляризованной сосудистой системы указанного матрикса ткани или органа композицией, включающей чистую популяцию эндотелиальных клеток или эндотелиальных клеток-предшественников. При трансплантации реципиенту ткани или матрикса органа выявляется очень малая тромбогенность. 13 з.п. ф-лы, 7 ил., 1 табл., 14 пр.

СПОСОБ ПОЛУЧЕНИЯ ИМПЛАНТАТА С ПЕРСОНИФИЦИРОВАННОЙ ПОВЕРХНОСТЬЮ

Изобретение относится к области стоматологии. Способ получения имплантата с персонифицированной поверхностью, включающий очистку/активацию поверхности имплантата с использованием плазменной технологии с помощью кислородной или аргоновой плазмы для получения поверхностей, не содержащих органических соединений или оксидных слоев, и нанесение жидкого раствора, приготовленного специально для каждого пациента и содержащего один остеокондуктивный, остеоиндуктивный, антибиотический, антибактериальный или пробиотический компонент или комбинацию нескольких таких компонентов. Очистка/активация поверхности имплантата с использованием плазменной технологии может осуществляться в клинике или на заводе по производству имплантатов, а жидкий раствор может наноситься в стоматологической клинике непосредственно перед установкой имплантата. 2 з.п. ф-лы.

СПОСОБ ПОЛУЧЕНИЯ ОСТЕОПЛАСТИЧЕСКОГО МАТЕРИАЛА

Изобретение относится к медицине, а именно к способу получения остеопластического материала. Способ включает механическую очистку кости от мягких тканей и распиловку губчатой костной ткани, обработку гипертоническим раствором хлористого натрия с концентрацией 1-10% в течение 1-8 суток, помещение материала в ультразвуковую ванну с раствором перекиси водорода с концентрацией 1-10% на 1-8 суток, глубокую очистку и делипидизацию методом сверхкритической флюидной экстракции при температуре 20-70°С и давлении 1000-10000 psi в течение 30-500 минут, деминерализацию соляной кислотой 0,5-4 М в течение 15-300 минут и лиофилизацию в течение 1-48 часов. Технический результат – проведение глубокой и безопасной очистки костного матрикса, сохранение структуры костного матрикса и нативных морфогенетических белков, снижение антигенности, повышение биосовместимости и остекондуктивности. 3 пр.

Способ получения конъюгированных гидрогелей на основе поли-N-изопропилакриламида, растворимой фракции гликопротеинов и гликозаминогликанов эндометриального внеклеточного матрикса и тромбоцитарного лизата

Настоящее изобретение относится к способу получения конъюгированного гидрогеля на основе поли-N-изопропилакриламида, растворимой фракции гликопротеинов и гликозаминогликанов эндометриального внеклеточного матрикса (эВКМ) и тромбоцитарного лизата (ТЛ), включающему, собственно, синтез поли-N-изопропилакриламида и его конъюгацию с биологически активными компонентами и отличающемуся тем, что его проводят в две стадии: - синтез поли-N-изопропилакриламида (ПНИПААм), включающий радикальную полимеризацию N-изопропилакриламида в деионизованной воде (ДВ) с сопротивлением 18 мегаОм, при использовании в качестве инициатора персульфата калия (ПСК) и мета-бисульфита натрия в качестве инициатора окисления-восстановления и со-инициатора соответственно, для чего N-изопропилакриламид (НИПААм) растворяют в ДВ в концентрации 5 масс. %, помещают в реактор и дегазируют в ультразвуковой ванне 2-3 минуты, затем вносят в систему инициатор полимеризации ПСК и метабисульфит натрия в концентрации по 0,05 масс. % каждого ...

Способ профилактики рубцово-спаечного процесса лучевого нерва после остеосинтеза переломов плечевой кости

Изобретение относится к медицине, а именно к травматологии, ортопедии и нейрохирургии, и может быть использовано для профилактики образования рубцово-спаечного процесса лучевого нерва после остеосинтеза переломов плеча. После остеосинтеза диафизарного перелома плеча пластиной между выделенным лучевым нервом и костными отломками плечевой кости укладывают заменитель твердой мозговой оболочки, который вырезают по длине выделенного лучевого нерва и накладывают гладкой стороной к нерву, перед этим лоскут смачивают стерильным физиологическим раствором. Лоскут фиксируют атравматичными швами к мягким тканям. Способ предотвращает сращение лучевого нерва и окружающих кость мягких тканей и уменьшает риск развития осложнений за счет образования между лучевым нервом и плечевой костью прослойки из коллагеновой ткани. 4 ил., 3 пр.

БИОСИНТЕТИЧЕСКИЕ УСТРОЙСТВА

СПОСОБ ИНАКТИВАЦИИ КСЕНОАНТИГЕНОВ В БИОЛОГИЧЕСКИХ ТКАНЯХ

FGF-18 В ПРОЦЕДУРАХ ПЕРЕСАДКИ ТРАНСПЛАНТАТА И ТКАНЕВОЙ ИНЖЕНЕРИИ

СПОСОБ ПОЛУЧЕНИЯ ИМПЛАНТАТА С ПЕРСОНИФИЦИРОВАННОЙ ПОВЕРХНОСТЬЮ

СТЕРИЛЬНЫЙ АУТОЛОГИЧНЫЙ, АЛЛОГЕННЫЙ ИЛИ КСЕНОГЕННЫЙ ИМПЛАНТАТ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

... 1. Бесклеточный стерильный практически дегидратированный и по меньшей мере частично денатурированный матрикс, полученный из ткани животного и содержащий преимущественно коллаген, фибриллы которого имеют такую же структурную организацию, как и в оригинальной ткани, предназначенный для применения в качестве временного имплантата в медицине и ветеринарии, отличающийся тем, что он претерпевает анизотропные изменения своих измерений во время гидратации. ! 2. Бесклеточный матрикс по п.1, отличающийся тем, что во время анизотропного изменения своих измерений во время гидратации два наибольших измерения остаются практически неизменными или уменьшаются, в то время как наименьшее измерение увеличивается вместе с увеличением объема матрикса. ! 3. Бесклеточный матрикс по п.2, отличающийся тем, что временный имплантат имеет преимущественно плоскую форму, а его опорная поверхность определяется двумя его наибольшими измерениями, в то время как его толщина определяется наименьшим его измерением. ! 4. Бесклеточный ...

Verfahren zur antiviralen Behandlung von biologischen Geweben mit Kollagentextur

Membrane

Improvements relating to decellularisation of tissue matrices for bladder implantation

Medical graft products with differing regions

Porous matrix

FLEXIBLE PROSTHESES OF PREDETERMINED SHAPES AND PROCESS FOR MAKING SAME

Methods for producing medical graft products with differing regions

Implantable materials and methods for inhibiting tissue adhesion formation

BONE-GRAFTING MATERIAL

Particulate cartilage compositions and regenerating cartilage

POROUS SYNTHETIC MATERIALS

... 1455360 Artificial body parts RESEARCH CORP 29 March 1974 [30 March 1973] 14133/ 74 Heading A5R [Also in Division C1] Synthetic phosphate biomaterials, useful in the manufacture of prosthetic devices or for use as implants in human hard tissue, are prepared by hydrothermal chemical exchange of porous carbonate skeletal material, retaining the original skeletal microstructure. The carbonate material may be derived from skeletal calcite or araganite of named maim animals and may comprise whitlockite or hydroxyaputite. The material may be shaped into cylinders, flat or curved sheets or screw-like forms for prosthesis or parts thereof or may be used to replace hard tissue e.g. bone.

Tissue graft composition and method

METHOD FOR PRESERVING TRANSPLANTABLE SHEETS OF EPITHELIUM CULTURED IN VITRO

Manufactoring process of a material for osteoplasty starting from a natural bone tissue and material obtained by this process

INJECT-CASH FIBRIN COMPOSITION FOR BONE REINFORCEMENT

POROUS MATRIX

INJECT-CASH CAVITY FILLER FOR SOFT FABRIC ENLARGEMENT

PRODUCTION OF K�RPERORGANEN BY KONTROLIERTES CELL GROWTH ON K�NSTLICHER MATRIX

PROCEDURE FOR COATING SCHLAUCHFOERMIGEN PROSTHESES, IN PARTICULAR CONTAINER PROSTHESES.

AUTOGENOUS, MARK ABSTENTION KOLLAGENMISCHUNG FOR BONE REPLACEMENT.

VERFAHREN ZUR BEHANDLUNG VON MENSCHLICHEM ODER TIERISCHEM BLUT

PROCEDURE FOR THE NETWORKING FABRICS OR BIOLOGICAL MATERIALS MANUFACTURED BY KOLLAGEN BY INTRODUCTION OF GROUPS OF AZIDES AND BY THIS PROCEDURE.

DEVICE AND PROCEDURE FOR THE PRODUCTION OF A KOMPOSITHAUTERSATZES.

OSTEOGENES PREPARATION ON THE BASIS FROM KOLLAGEN TO REPAIRING BONE DEFECTS.

DISCOVERABLE ARTIFICIAL ONES OF BIO IMPLANTS

IN VITRO PROCEDURES FOR MANUFACTURING A HOMOLOGOUS HERZKLAPPEN OR CONTAINER PROSTHESIS

DISSECTION OF BONES FOR THE TRANSPLANT

Sheet-like decellularized material and artificial blood vessel employing said material

The present invention relates to a sheet-like decellularized material of biological material origin, wherein the maximum value of the tensile strengths in four directions is equal to or greater than 4 MPa, and the expansion rate in the direction in which the tensile strength reaches the maximum is 50% to 300%. The present invention provides a sheet-like material that is capable of maintaining a superior pressure resistance when used as a blood vessel or when used to repair a blood vessel.

Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method for preparation thereof

Process for preparing an osseous ceramic material and bone regenerating and growth promoting composition

Method and device for synovial cell-charged collagen membrane or gel

An implant for repair of a cartilaginous defect in a subject includes a collagen matrix charged with synovial cells. A method preparing an implant for repair of a cartilaginous defect in a subject includes obtaining a fluid containing synovial cells and charging the synovial cells to the matrix. A device for preparing a cell-charged implant includes a first chamber and a second chamber, the first and second chambers being separated by a membrane and a perforated filter. The membrane is adapted to collect cells from a cell-containing fluid introduced into the first chamber and the perforated filter is adapted to permit passage or diffusion of the fluid through the second chamber. A method for preparing a cell-charged implant utilizes the device.

Collagen-based materials and methods for augmenting intervertebral discs

Preparation of tissue for meniscal implantation

The present invention relates to a method of preparing a tissue matrix and its subsequent use in the replacement and/or repair of a damaged or defective meniscus. The invention also provides meniscal tissue that is substantially decellularised.

Method for removal of water associated with bone while diminishing the dimensional changes associated with lyophilization

Compositions and methods for anti-LYST immunomodulation

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to mtimal hyperplasia and fibrotic disease. It has been established that inhibition of the LYST protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage. Compositions and methods for inhibition of the expression and function of the LYST protein are described. The compositions and methods can be useful for the modulation of immune processes that contribute to formation of neointima and fibroproliferative disorders by altering macrophage, platelet and natural killer cell function to create a pro- regenerative immune response.

Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix

Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

Micronized Wharton's jelly

The present invention provides compositions and formulations of micronized Wharton' s jelly having a controlled viscosity such that when delivered to the injured region of a subject, it remains substantially localized with little or no migration out of the injured region for the repair and/or regeneration thereof. Micronized Wharton's Jelly can be suspended in a pharmaceutically acceptable aqueous carrier, such as saline, sterile water, or any suitable buffer, to form a suspension or a gelatinous gel composition, or it can be in the form of a paste, suitable for delivery into the space adjacent the articular surface cartilage injured region of a subject. The micronized Wharton's jelly when employed at sufficient concentrations can be hydrated into a gel or paste and administered topically, or it can be injected into the body through the use of a needle and syringe.

Method for enzymatic treatment of tissue products

Disclosed is a multi-needle module used for a sewing machine, capable of being attached and installed on an existing sewing machine, and capable of conveniently refitting an existing sewing machine into a multi-needle sewing machine. The multi-needle module is not limited to a twin-needle structure and can be equipped with three needles, four needles or even more needles according to needs, solving the problem of a single-needle sewing machine and a twin-needle sewing machine having insufficient varieties of upper thread colour when sewing a pattern and thus requiring manual exchange of threads. The multi-needle module guides each needle (4) by means of a first horizontal guide groove (11) and a second horizontal guide groove (12), and feeds a specific needle into a snap-groove (5a) of a needle driving block (5) by means of a driving mechanism, and has the advantages of a simple structure and automated control.

Improvements Relating to Decellularisation of Tissue Matrices for Bladder Implantation

The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the 5 bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material, The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.

Intervertebral spacer

TISSUE GRAFT COMPOSITION AND METHOD

METHOD FOR MANUFACTURING A THREE-DIMENSIONAL BIOMEDICAL DEVICE HAVING REGIONS OF DIFFERING POROSITY OBTAINED BY A LASER FUSION OF A POWDER

This invention relates to a three-dimensional biomedical device, having an osteoinductive first area with a controlled porosity and a second area, the device being produced by a laser technology from a powder comprising ceramics; and/or metals; and/or metal alloys; and/or bioactive glasses; and/or lead zirconate titanate; and/or biocompatible polymers and/or mixtures thereof, the ratio of the porosity of the second area to the porosity of the first area being equal or less than one, preferably ranging from 0,001 to 0,9; this invention also relates to a method for manufacturing a biomedical device for fitting in a bone defect wherein an image of the defect is performed, from this image, a virtual object is designed with a computer-aid designed software, optionally, a scale model is performed, and the biomedical device is manufactured by a laser technology comprising layering a powder of particles onto a plate (7) so that a layer of a predetermined thickness is formed on the plate (7), and ...

METHOD FOR PREPARING AN ACELLULAR ORGANIC TISSUE OF HUMAN OR ANIMAL ORIGIN FOR REVITALIZATION

The invention concerns a method for the preparation of an acellular organic tissue of human or animal origin for revitalization, in particular for the introduction of living cells, comprising a stage in which the acellular organic tissue (2; 12) is provided with a plurality of holes (4; 14) made through its surface (8; 18) and extending towards the inside of the tissue (2; 12), wherein the plurality of holes (4; 14) is made by means of one or more needles. The holes (4; 14) intersect partially, thus forming holes (4; 14) partially communicating with each other.

METHOD FOR PREPARING AN ACELLULAR ORGANIC TISSUE OF HUMAN OR ANIMAL ORIGIN FOR REVITILIZATION

The invention concerns a method for the preparation of an acellular organic tissue of human or animal origin for revitalization, in particular for the introduction of living cells, comprising a stage in which the acellular organic tissue (2; 12) is provided with a plurality of holes (4; 14) made through its surface (8; 18) and extending towards the inside of the tissue (2; 12), wherein the plurality of holes (4; 14) is made by means of one or more needles. The holes (4; 14) intersect partially, thus forming holes (4; 14) partially communicating with each other. The invention also concerns a corresponding acellular organic tissue (2; 12) of human or animal origin prepared for revitalization, in particular for the introduction of living cells, comprising holes (4; 14) that are punctures made with needles and extending from the surface of the tissue (8; 18) towards its inside. The holes (4; 14) intersect at least partially and are therefore holes (4; 14) partially communicating with each other ...

BONE-GRAFTING MATERIAL

A bone grafting material is derived from allogenic or xenogenic bone by a process that includes tanning with glutaraldehyde. The bone may be pulverized, used as a large block, or machined into a precise pre-determined shape, depending on the bone defect to be repaired. Glutaraldehyde tanning of bone yields a stabilized, highly biocompatible, and non-antigenic materral which becomes incorporated into host bone when placed adjacent to it.

A MEDICAL PROCEDURE KIT AND A RELATED METHOD

The present disclosure provides a medical procedure kit for ameliorating tissue damage in a patient, the kit comprising a container enclosing a receptacle, an extractor for extracting biological material including autologous cells from the patient, a strainer for straining autologous cells from the biological material and an implantable support having a surface onto which the autologous cells can adhere, the implantable support configured to be received by the receptacle. Also disclosed are related methods of manufacturing a medical material and using the medical procedure kit.

IMPROVEMENTS RELATING TO DECELLULARISATION OF TISSUE MATRICES FOR BLADDER IMPLANTATION

The invention provides an improved method of producing a natural, acellul ar matrix scaffold for subsequent use in tissue-engineered replacement of ti ssues such as the bladder. Decellularisation is carried out on an expanded o r distended bladder and the product retains the strength and compliance of n atural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in v itro.

FISTULA GRAFTS AND RELATED METHODS AND SYSTEMS FOR TREATING FISTULAE

Described are medical graft products, systems, and methods for treating fistulae. Certain products of the invention are configured to have portions residing in and around a primary fistula opening, e.g., one occurring in a wall of the alimentary canal. One such product includes a biocompatible graft body which is configured to block at least the primary opening. The graft body includes a capping member (280), which is configured to contact portions of the alimentary canal wall adjacent to the primary opening, and an elongate plug member (282) extending from the capping member, which is configured to extend into at least a portion of the fistula. In certain embodiments, a graft body component has the capacity to expand or otherwise change form to provide a suitable capping arrangement. Such a component can include a resilient wire frame, e.g., one that is self -expandable or one that requires at least some manipulation in order to expand.

COMPOSITIONS AND METHODS FOR REGENERATION OF HARD TISSUES

Bone graft compositions including bioactive glass scaffold and characterized in that the bioactive glass scaffold has a high compressive strength, is osteoconductive and osteostimulative and resorbs at a rate consistent with the formation of new bone are described. Also, methods of using the bone grafts for regeneration of hard tiss ues and, especially, for treating or correcting developmental dysplasia of the hip are provided.

BONE REGENERATION MATERIAL AND MANUFACTURE METHOD THEREOF

Procédé comprenant: - une mise en contact d'un matériau osseux contenant de l'hydroxyapatite et des substances organiques avec un liquide d'extraction qui donne lieu à une première phase liquide contenant lesdites substances organiques et éventuellement des impuretés extraites dudit matériau osseux et à une deuxième phase hydroxyapatite solide contenant ladite hydroxyapatite, et - une séparation entre ladite phase liquide et ladite phase hydroxyapatite solide, ledit liquide d'extraction étant une solution aqueuse d'extraction amenée à une température comprise entre 150°C et 300°C et à une pression comprise entre 150 kPa et 350 kPa.

METHODS FOR PREPARATION OF A TERMINALLY STERILIZED HYDROGEL DERIVED FROM EXTRACELLULAR MATRIX

Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

STERILE AUTOLOGOUS, ALLOGENIC OR XENOGENIC IMPLANT AND THE METHOD OF ITS PRODUCTION

The subject of the invention is a sterile, dehydrated acellular implant, which during its rehydration by water or bodily fluids displays anisotropic expansion and can act as a substrate for adhesion, migration and growth of live cells. Collagen structures of the transplant are at least partially denatured through the action of heat or organic solvents, such as lower aliphatic al-cohols and ketones, which simultaneously act as preservative and sterilization agents, especially for certain types of viruses. The implant is sterilized by radiation while in an substantially dehydrated state, preferably by accelerated electrons. The transplant can be derived from various animal tissues, especially mammalian tissues, such as human or porcine tissues. The tissues suitable for the invention can be, for example, skin, placenta, pericardium, peritoneum, intestinal wall, tendon, blood vessel, etc. The implant is suitable for use in human and veterinary medicine, for instance as a temporary wound and ...

MULTI-LAYER TISSUE SYSTEMS AND METHODS

Embodiments of the present invention encompass anti-adhesion wound dressings including patches made from amnion tissue obtained from human birth tissue. Exemplary amnion patches can be fabricated by folding a section of amnion over on itself with the epithelial layer on the outside of the folded patch and the fibroblast layer on the inside of the folded patch. Optionally, individual amnion tissue pieces can be sandwiched together to provide a multi layer patch. Sufficient pressure is applied to the layered amnion to cause adherence between opposing faces of the fibroblast layers. The pressed fibroblast layers provide mechanical strength to hold the amnion patch together with the epithelial layers on the outsides of the amnion patch.

HYDROPHILIC PHOSPHATE GROUP CONTAINING DEHYDRATED PARTIALLY PURIFIED BONE REPLACEMENT MATERIAL

The invention provides: - A hydrophilic dehydrated partially purified bone replacement material of natural origin, wherein substantially all non-collagenous organic material is removed while inorganic, porous osseous structure and collagenous structure of natural bone are substantially preserved, characterized in that the bone replacement material contains 0.05 to 1.5 w/w % of at least one of a saccharide or a sugar alcohol, and 0.7 to 5.6 w/w % of a phosphate group selected from the group consisting of phosphate HPO42- and H2PO4 -, this phosphate group being part of a physiologically acceptable salt and - a process for preparing a hydrophilic dehydrated partially purified bone replacement material.

REINFORCED PLACENTAL TISSUE GRAFTS AND METHODS OF MAKING AND USING THE SAME

Described herein are tissue grafts derived from the placental tissue that are reinforced with at least one biocompatible mesh. The tissue grafts possess good adhesion to biological tissues and are useful in wound healing applications. Also described herein are methods for making and using the tissue grafts.

NATURAL TISSUE HEART VALVE FIXATION

A natural tissue heart valve includes a tubular wall (13) having an outflow section (19) and valve leaflets (15) which allow flow into the outflow section (19). A heart valve (11) of this type is subjected to a fixative fluid to provide a first differential fluid-pressure across the tubular wall (13) of the outflow section (19) and a second differential fluid pressure across the valve leaflets (15). The first differential fluid pressure acts outwardly on the tubular wall (13), and the differential pressures are unequal.

BIOLOGICALLY COMPATIBLE COLLAGENOUS REACTION PRODUCT AND ARTICLES USEFUL AS MEDICAL IMPLANTS PRODUCED THEREFROM

The present invention provides a biologically com- patible collagenous reaction product comprising ethylenically unsaturated monomerically substituted collagen, the monomeric substituents being essentially free of nitrogen, e.g., methy- acrylate, styrene, polyvinyl, ethylene. The collagenous reaction product can be polymerized, e.g., by exposure to UV irradiation, chemical agents or atmospheric oxygen, and molded to form useful medical implant articles. Methods of prepara- tion are also provided.

USE OF A COLLAGEN MEMBRANE IN PREPARATION OF AN IMPLANT FOR GUIDED TISSUE REGENERATION

The invention relates to a resorbable collagen membrane for use in guided tissue regeneration wherein one face of said membrane is fibrous thereby allowing cell growth thereon and the opposite face of said membrane is smooth, thereby inhibiting cell adhesion thereon. Such a membrane is of particular use in the treatment of wounds and lesions.

MODIFIED OSTEOGENIC MATERIALS

A process and product comprising collagen and demineralized bone particles. The product may contain a maximum of 20 % by weight inorganic materials. The product may be densified by compression. Additional osteogenic factors, mitogens, drugs or antibiotics may be incorporated therein. Inorganic materials may be bound to the organic matrix via precoating with a calcium or hydroxyapatite binding protein, peptide or amino acid. The materials also display long lasting drug release characteristics. The subject of this invention is a process and resultant composition which increases the rate and predictability of osteoinduction by demineralized bone matrix. In particular, this invention relates to compositions of demineralized bone and calcium or other mineral salts which exhibit enhanced osteogenic potential. This invention further relates to osteogenic compositions comprising between about 60 % to 90 % demineralized bone by weight and to compositions comprising a carrier and alkaline phosphatase ...

KUENSTLICHES BONE SCREEN END BIOLOGICAL MATERIAL AND THIS CONTAINING IMPLANTATION MATERIAL.

PROCEDURE FOR A CAPS OF A CHEMICALLY ACTIVE NUCLEAR MATERIAL.

PROCEDURE FOR COATING SCHLAUCHFOERMIGEN PROSTHESES FROM PLASTIC.

FABRIC TRANSPLANT.

FABRIC TRANSPLANT.

Bone material and Kollagen combination to the repair of injured joints.

PROCEDURE FOR A CAPS OF A NUCLEAR MATERIAL WITHIN A SEMIPERMEABLE DIAPHRAGM.

GLANDULA PROSTHESIS.

PRESSURE FLOW SYSTEM AND METHOD OF TREATMENT OF LIQUID STNO - PERMEABLE BLANKS, SUCH AS BONE

CELL ENCAPSULATION DEVICES CONTAINING STRUCTURAL SPACERS

THREE-DIMENSIONAL PERMEABLE MATTER OF WIDE SURFACE

ARTIFICIAL BODY, In the form of MICROCAPSULES, BEING APPROPRIATE FOR ITS ESTABLISHMENT IN the BODY Of a MAMMAL

NEW USES Of a SUPERCRITICAL CARBON DIOXIDE CURRENT AS ANTIVIRAL AGENT

Procédé d'encapsulation d'un tissu viable ou d'une matière biologiquement active à implanter, et capsules obtenues.

L'INVENTION CONCERNE L'ENCAPSULATION DE FRAGMENTS D'UN TISSU VIABLE OU D'UNE MATIERE BIOLOGIQUEMENT ACTIVE A IMPLANTER DANS UN CORPS DE MAMMIFERE, ET LES CAPSULES OBTENUES. ON MET LE TISSU VIVANT FINEMENT DIVISE EN SUSPENSION DANS UN MILIEU AQUEUX PHYSIOLOGIQUEMENT COMPATIBLE AVEC LUI ET QUI CONTIENT UNE GOMME OU SUBSTANCE HYDROSOLUBLE COMPATIBLE AVEC LE TISSU ET POUVANT ETRE GELIFIEE A; ON TRANSFORME LA SUSPENSION EN DES GOUTTELETTES DE DIMENSIONS SUFFISANTES POUR ENVELOPPER LE TISSU BC; ON GELIFIE LES GOUTTELETTES POUR FORMER DES CAPSULES TEMPORAIRES SEPAREES ET CONSERVANT LEUR FORME D, E; ET L'ON FORME A F UNE MEMBRANE PERMANENTE 24 AUTOUR DES CAPSULES TEMPORAIRES CONTENANT LE TISSU 26 ET SES CELLULES 28. INJECTEES A LA SERINGUE DANS LE CORPS D'UN MAMMIFERE, DES CAPSULES DE CELLULES DE FOIE OU DE PANCREAS PEUVENT Y JOUER LE ROLE D'UN ORGANE ARTIFICIEL.

ARTIFICIAL BIOMATIERE OSTEOFORMATRICE AND ITS MANUFACTORING PROCESS

PROCESS Of OBTAINING a BIOPOLYMERE RETICULATES CONTAINING COLLAGEN, IMPLANT OBTAINED OF THIS BIOPOLYMERE AND PROCESS Of OBTAINING THIS IMPLANT

METHOD OF ENCAPSULATING A VIABLE TISSUE OR OF A BIOLOGICALLY ACTIVE MATERIAL FOR IMPLANTATION, AND CAPSULES OBTAINED

PROSTHESIS FOR the REPLACEMENT Of an ARTICULAR CARTILAGE AND ITS PROCESS OF PRODUCTION

A METHOD FOR MANUFACTURING AN OSTEOSYNTHESIS, OSTEOSYNTHESIS DEVICES AND IMPLANTS IN SEMI-SYNTHETIC HYBRID MATERIAL OBTAINED BY STRUCTURAL MODIFICATION OF COMPONENTS OF A MARINE NATURAL BIOMATERIAL

La présente invention porte sur un matériau hybride semi-synthétique qui comprend une fraction inorganique et une fraction organique, présentant un pH de 7 à 7,4 et dans lequel ladite fraction organique est réticulée, sur le procédé de fabrication de ce matériau et sur des dispositifs d'ostéosynthèse ou implants en matériau hybride semi-synthétique .

염증성 장 질환을 치료하기 위한 방법 및 조성물

... 병든 또는 손상된 조직, 예를 들면, 염증성 장 질환, 예를 들면, 궤양성 대장염을 치료하기 위한 방법 및 조성물은 손상된 조직으로의 줄기 세포 이주를 자극하는 줄기 세포 또는 조직 이식편을 이용한 조직 재생을 포함한다. 이들 조직 이식편은 세포외 기질 (ECM) 물질, 예를 들면, 조직 특이적 세포외 기질 (TS-ECM)일 수 있다. 이들 방법은 또한, 이식편의 배치에 앞서, 손상된 또는 병든 조직의 점막 적출을 포함할 수 있다.

BONE PASTE

STAND-ALONE FILM AND METHODS FOR MAKING THE SAME

A stand-alone film is derived at least in part from fatty acids. The stand-alone film can have anti-adhesive, anti-inflammatory, non-inflammatory, and wound healing properties, and can additionally include one or more therapeutic agents incorporated therein. Corresponding methods of making the stand-alone film include molding, casting, or otherwise applying a liquid or gel to a substrate, and curing or otherwise treating to form the stand-alone film. The resulting stand-alone film is bioabsorbable.

BIOMEDICAL DEVICE, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF

This invention relates to a three-dimensional biomedical device, having an osteoinductive first area with a controlled porosity and a second area, the device being produced by a laser technology from a powder comprising ceramics; and/or metals; and/or metal alloys; and/or bioactive glasses; and/or lead zirconate titanate; and/or biocompatible polymers and/or mixtures thereof, the ratio of the porosity of the second area to the porosity of the first area being equal or less than one, preferably ranging from 0,001 to 0,9; this invention also relates to a method for manufacturing a biomedical device for fitting in a bone defect wherein an image of the defect is performed, from this image, a virtual object is designed with a computer-aid designed software, optionally, a scale model is performed, and the biomedical device is manufactured by a laser technology comprising layering a powder of particles onto a plate (7) so that a layer of a predetermined thickness is formed on the plate (7), and ...

SYNTHETIC STRUCTURE FOR SOFT TISSUE REPAIR

Synthetic structures for fibrous soft tissue repair include a polymeric fibrillar structure that exhibits mechanical properties of the human fibrous soft tissue.

GRAFT DEVICES AND METHODS OF FABRICATION

A graft device is provided comprising a flow conduit and a surrounding covering. The graft device can connect a first body space and a second body space. In one embodiment, the flow conduit is a vein, such as a harvested saphenous vein, useful as an arterial graft, for example and without limitation, in a coronary artery bypass procedure. Also provided are methods of preparing a graft device and connecting the graft device between a first body space and a second body space, such as the aorta and a location on an occluded coronary artery, distal to the occlusion.

QUANTITATIVE IN VITRO BONE INDUCTION ASSAY

An in vitro assay for quantifying the osteogenic capacity of bone implants involves in vitro isolation and quantitation of specific osteogenic factors. The method disclosed permits direct measurement of the osteogenic capacity of an implant to allow greater predictability of the degree to which new bone will grow in a given area. The method eliminates the need to practice the traditional technique of implanting material into a test animal and subsequently sacrificing the animal to assess bone growth associated with the implant. Since the present method does not involve animal testing, it is an extremely reproducible, rapid, and accurate method for predicting whether an implanted composition or material will induce bone growth without the need for in v ivo assays.

PERICARDIAL ANTI-ADHESION PATCH

The present invention is directed to an anti-adhesion patch (1A), which is constructed using a tissue equivalent technique. The anti-adhesion patch (1A) comprises a collagenous material and at least one non-living cellular component. Also provided is a method for preventing tissue adhesions between organs and other tissues being operated upon during surgical procedures by utilizing the anti-adhesion patch (1A) disclosed herein.

Drug-eluting device chemically treated with genipin

A method for treating a target tissue of a patient comprising, in combination, mixing a drug with a solidifiable biological material, chemically treating the drug with the biological material with a crosslinking agent, loading the solidifiable drug-containing biological material onto a medical device, solidifying the drug-containing biological material; and delivering the medical device to the target tissue for treating the tissue.

Prosthetic device and method of using in breast augmentation and/or breast reconstruction

A method of using a biocompatible surgical knitted, silk scaffold device in a breast augmentation or in a breast reconstruction cosmetic or surgical procedure such as single-stage or two-stage breast reconstruction. In an aspect of the invention, the silk scaffold employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh or scaffold device, especially when the mesh or scaffold device is cut. An example scaffold device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. The second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes.

Heart valve prosthesis using different types of living tissue and method of fabricating the same

A heart valve prosthesis and a method of fabricating the same. The heart valve prosthesis uses a leaflet of pig pericardium or a leaflet of cattle pericardium, which has a suitable thickness according to the size of the valve, and a stent. The heart valve prosthesis is fabricated by placing a valve body over a Dacron body, binding the valve body to the Dacron body using stitching fiber, rolling the Dacron body into a cylindrical form such that the valve body is located inside, binding opposite edges of the Dacron body to each other using stitching fiber, and inserting the resultant structure into a stent, which is knitted using a shape memory alloy wire. The heart valve prosthesis is friendly to and is not rejected by human tissue, is free from deformation, and can be implanted using a non-invasive manner without incising the chest wall of a patient.

Extracellular matrix compositions for tissue regeneration

The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.

Biologic treatment system and method

A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Multi-layer tissue systems and methods

Embodiments of the present invention encompass anti-adhesion wound dressings including patches made from amnion tissue obtained from human birth tissue. Exemplary amnion patches can be fabricated by folding a section of amnion over on itself with the epithelial layer on the outside of the folded patch and the fibroblast layer on the inside of the folded patch. Optionally, individual amnion tissue pieces can be sandwiched together to provide a multi-layer patch. Sufficient pressure is applied to the layered amnion to cause adherence between opposing faces of the fibroblast layers. The pressed fibroblast layers provide mechanical strength to hold the amnion patch together with the epithelial layers on the outsides of the amnion patch.

Osteoinductive bone graft injectable cement

Osteoconductive bone graft materials are provided. These compositions contain injectable cements and demineralized bone matrix fibers. The combination of these materials enables the filling of a bone void while balancing strength and resorption.

Apparatus for forming an implant

Implants for repairing tissue defects, such as cartilage tissue defects, and methods of their preparation and use are disclosed. A mold of a tissue defect is prepared by pressing upon the defect a substrate having shape memory, such as aluminum foil. The mold, which has contours substantially conforming to those of the defect, is removed from the defect, and tissue particles are added to the mold ex vivo. A biological carrier such as biocompatible glue is also added to the mold. The combination of tissue particles and the biological carrier thereby form an implant, which retains its shape after separation from the mold. The implant can be transferred to the tissue defect, with contours of the mold matching corresponding contours of the defect.

Tubular silk compositions and methods of use thereof

Described are tubular silk fibroin compositions and methods for their manufacture and use. Tubular compositions as described herein can be produced in a range of high burst strengths, can easily be made in a range of inner diameters, can be derivatized with functional moieties, and can be produced in a range of permeabilities suitable for particularized uses. In one aspect, the tubular compositions can be used in the repair or replacement of damaged or diseased blood vessels, including, but not limited to vessels smaller than about 6 mm.

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Cell coated implantable device

The present invention relates, in general, to a cell-coated implantable medical device and, in particular, to an implantable medical device the blood-contacting surfaces of which are coated with endothelial progenitor cells (EPCs). In a preferred embodiment, the medical device is a titanium or titanium alloy-based medical device.

Umbilical cord amniotic membrane products

Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.

Implantable material and a method for the preparation thereof

A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between −0.001 and −0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between −0.001 and −0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.

STENT GRAFT WITH TWO LAYER ePTFE LAYER SYSTEM WITH HIGH PLASTICITY AND HIGH RIGIDITY

A vascular prosthesis and method are disclosed comprising a first flexible stent having a lattice structure with a compacted configuration and an expanded configuration, a second flexible stent inside the first flexible stent to form a tubular structure, a first film layer of graft material such as expanded polytetrafluoroethylene sandwiched between the first and second flexible stents, and a second film layer of expanded polytetrafluoroethylene sandwiched between the first and second flexible stents, the second layer having a higher rigidity and a lower plasticity than the first layer.

Compositions and improved soft tissue replacement methods

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Cartilage Repair

This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.

Immunoneutral silk-fiber-based medical devices

Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties.

Process for demineralization of bone matrix with preservation of natural growth factors

A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.

Extracellular matrix material created using non-thermal irreversible electroporation

Extracellular matrix material is disclosed which is created by subjecting a target area to non-thermal irreversible electroporation (NTIRE) with a pulsed electrical field to kill cells in the absence of thermal damage. The dead cellular material may be removed and the remaining non-cellular matrix material may be implanted into a repair site to be treated medically or cosmetically.

Tissue transplant compositions and methods for use

Provided are transplants and methods for augmenting formation and restoration of organ and tissue, for example, bone formation, by administering autologous or allogeneic human embryonic-like adult stem cells (ELA cells). Also provided is a method for augmenting formation of tissues and organs by administering a transplant having ELA stem cells or combination of ELA stem cells.

Compositions for bone tissue repair and uses thereof

The technology described herein relates to compositions for promoting bone growth or regeneration. The compositions described herein can comprise bioactive agents and scaffold materials.

Productions of artificial tissues by means of tissue engineering using agarose-fibrin biomaterials

The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ.

Artificial skin

The present invention relates to a method for producing artificial skin, comprising: adding a matrix metalloproteinase inhibitor and a heparanase inhibitor to an artificial skin formation culture medium comprising human epidermal keratinocytes and human dermal fibroblasts, culturing the cells in the artificial skin formation culture medium, and forming artificial skin.

Collagen fiber constructs for replacing cruciate ligaments

The present invention relates to a collagen fiber construct composed of single collagen fibers, which is sterilized with alcohol and via irradiation and not populated with cells, wherein the single collagen fibers are isolated from collagen-containing tissue from mammals. The present invention also relates to a method for manufacturing a collagen fiber construct composed of single collagen fibers, which is sterilized with alcohol and via irradiation and is not populated with cells, wherein the single collagen fibers are isolated from collagen-containing tissue from rat tails. Finally, there is also described the use of the collagen fiber constructs as xenoimplants.

Crosslinked human or animal tissue products and their methods of manufacture and use

Degradable bioprostheses made of collagen-based material having amine-based and ester-based crosslinks are provided, as are methods for their formation and use. Some embodiments of the present invention are directed towards a method of controlling the ratio of amine-based crosslinks to ester-based crosslinks within a collagen-based material to provide a tailorably crosslinked collagen-based material. Some embodiments provide a method of making a degradable bioprosthesis involving controlling crosslinking to afford a degradable bioprosthesis that is partially crosslinked. By controlling the ratio of amine-based to ester-based crosslinks, by controlling the level of crosslinking, or by controlling both of these features, degradable bioprostheses with tailored degradation rates can be synthesized. Some embodiments of degradable bioprostheses have degradation rates that are tailored to allow their use in particular medical applications. Some embodiments are directed towards methods of use degradable bioprostheses in wound healing, tissue repair, and tissue supplementation.

Engineered Tissue Implants And Methods Of Use Thereof

A engineered tissue implant comprising a perfusion chamber formed with a biocompatible flexible tubular member having a wall defining an internal fluid flow passage and a porous scaffold within the fluid flow passage of the tubular member, the porous scaffold arranged such that, in a presence of a perfusion fluid, the perfusion fluid will flow through the porous scaffold and be inhibited from flow between the porous scaffold and the wall of the tubular member. The engineered tissue implant may be understood as a transplantable cell construct or as an implantable bioreactor for cell growth both in vitro and/or in vivo. A method to provide tissue for reconstruction may comprise forming the engineered tissue implant containing a scaffold, introducing and seeding cells to the scaffold, introducing a perfusion fluid to the scaffold which flows through the fluid flow passage and scaffold, proliferating the cells within the scaffold and forming blood vessels within the scaffold. This may be followed by transplanting the engineered tissue implant in vivo where nutrition and oxygen are provided to support the preloaded cells.

Cytocompatible alginate gels

The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.

Methods and devices for preparing and implanting tissue scaffolds

Methods and devices are provided for preparing and implanting tissue scaffolds. Various embodiments of scribing tools are provided that are configured to mark one or more predetermined shapes around a defect site in tissue. The shape or shapes marked in tissue can be used to cut a tissue scaffold having a shape that matches the shape or shapes marked in tissue. In one embodiment, the scribing tool used to mark a shape in tissue can also be used to cut the tissue scaffold.

Device and method for replacing mitral valve

A prosthetic mitral valve assembly is disclosed. The assembly comprises a radially-expandable stent including a lower portion sized for deployment between leaflets of a native mitral valve and an upper portion having a flared end. The upper portion is sized for deployment within the annulus of the mitral valve and the flared end is configured to extend above the annulus. The stent is formed with a substantially D-shape cross-section for conforming to the native mitral valve. The D-shape cross-section includes a substantially straight portion for extending along an anterior side of the native mitral valve and a substantially curved portion for extending along a posterior side of the native mitral valve. The assembly further includes a valve portion formed of pericardial tissue and mounted within an interior portion of the stent for occluding blood flow in one direction.

Synthetic scaffolds and organ and tissue transplantation

Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided.

Bone Semi-Permeable Device

Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.

Hard-tissue implant

Hard-tissue implants are provided that include a bulk implant, a face, pillars, and slots. The pillars are for implantation into a hard tissue. The slots are to be occupied by the hard tissue. The hard-tissue implant has a Young's modulus of elasticity of at least 10 GPa, has a ratio of the sum of (i) the volumes of the slots to (ii) the sum of the volumes of the pillars and the volumes of the slots of 0.40:1 to 0.90:1, does not comprise any part that is hollow, and does not comprise any non-pillar part extending to or beyond the distal ends of any of the pillars. Methods of making and using hard-tissue implants are also provided.

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. 1. A composition comprising an extracellular matrix scaffold component that induces neovascularization , host tissue proliferation and bioremodeling of biological tissue , a protoeglycan and a drug , said extracellular matrix scaffold component being derived from a mammalian source selected from the group consisting of urinary bladder submucosa (UBS) and urinary basement membrane (UBM).2. The composition of claim 1 , wherein said protoeglycan comprises a matrix heparin sulfate protoeglycan. This application is a Divisional Application of U.S. application Ser. No. 11/182,551, filed on Jul. 15, 2005.The invention relates to tissue engineering generally, and more specifically to compositions and methods for regenerating defective or absent myocardium.Heart failure occurs in nearly 5 million people a year in the U.S. alone at a combined cost of about $40 billion annually for hospitalization and treatment of these patients. The results of all the effort and cost are disappointing with a 75% five year mortality rate for the heart failure victims. Treatments for chronic heart failure include medical management with pharmaceutical drugs, diet and exercise, transplantation for a few lucky recipients, and mechanical assist devices, which are costly and risk failure and infection. Thus the landscape for cardiac treatment is turning in recent years to transplantation of tissue or cells.Medical researchers have transplanted human hematopoetic stem cells, mesenchymal stem cells, endothelial precursor cells, cardiac stem cells, and skeletal myoblasts or bone marrow cells to the myocardium, with however little or ...

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. 1. A composition for restoring cardiac function comprising an extracellular matrix (ECM) scaffold derived from a mammalian source , a protoeglycan and a drug , said drug comprising an antiarrhythmic agent selected from the group consisting of quinidine , procainamide , diisopyramide , lidocaine , phenyloin , mexiletine , flecamide , propafenone , moricizine , propranolol , esmolol , timolol , metoprolol , atenolol , amiodarone , sotalol , ibutilide , dofetilide , verapamil , diltiazem , adenosine and digoxin.2. The composition of claim 1 , wherein said drug comprises an antibiotic selected from the group consisting of aminoglycosides claim 1 , cephalosporins claim 1 , chloramphenicol claim 1 , clindamycin claim 1 , erythromycins claim 1 , fluoroquinolones claim 1 , macrolides claim 1 , azolides claim 1 , metronidazole claim 1 , penicillins claim 1 , tetracyclines claim 1 , trimethoprim-sulfamethoxazole and vancomycin.3. The composition of claim 1 , wherein said drug comprises a narcotic analgesic selected from the group consisting of morphine claim 1 , codeine claim 1 , heroin claim 1 , hydromorphone claim 1 , levorphanol claim 1 , meperidine claim 1 , methadone claim 1 , oxycodone claim 1 , propoxyphene claim 1 , fentanyl claim 1 , methadone claim 1 , naloxone claim 1 , buprenorphine claim 1 , butorphanol claim 1 , nalbuphine and pentazocine.4. The composition of claim 1 , wherein said drug comprises an antiinflammatory selected from the group consisting of alclofenac claim 1 , alclometasone dipropionate claim 1 , algestone acetonide claim 1 , alpha amylase claim 1 , amcinafal claim 1 , amcinafide ...

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. 1. A composition comprising an extracellular matrix scaffold component derived from a mammalian source , a protoeglycan and a vector having a DNA capable of targeted expression of a selected gene.2. The composition of claim 1 , wherein said scaffold is formulated in a material form claim 1 , said material form comprising a patch.3. The composition of claim 1 , wherein said extracellular matrix scaffold component comprises small intestine submucosa (SIS). This application is a Divisional Application of U.S. application Ser. No. 11/182,551, filed on Jul. 15, 2005.The invention relates to tissue engineering generally, and more specifically to compositions and methods for regenerating defective or absent myocardium.Heart failure occurs in nearly 5 million people a year in the U.S. alone at a combined cost of about $40 billion annually for hospitalization and treatment of these patients. The results of all the effort and cost are disappointing with a 75% five year mortality rate for the heart failure victims. Treatments for chronic heart failure include medical management with pharmaceutical drugs, diet and exercise, transplantation for a few lucky recipients, and mechanical assist devices, which are costly and risk failure and infection. Thus the landscape for cardiac treatment is turning in recent years to transplantation of tissue or cells.Medical researchers have transplanted human hematopoetic stem cells, mesenchymal stem cells, endothelial precursor cells, cardiac stem cells, and skeletal myoblasts or bone marrow cells to the myocardium, with however little or mixed success in satisfactory ...

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. 1. An injectable composition for inducing cell differentiation into cardiomyocytes comprising a a decellularized extracellular matrix scaffold from a mammalian tissue source and a glycosaminoglycan (GAG) protein , said tissue source comprising cardiac tissue.23-. (canceled) This application is a Divisional Application of U.S. application Ser. No. 11/182,551, filed on Jul. 15, 2005.The invention relates to tissue engineering generally, and more specifically to compositions and methods for regenerating defective or absent myocardium.Heart failure occurs in nearly 5 million people a year in the U.S. alone at a combined cost of about $40 billion annually for hospitalization and treatment of these patients. The results of all the effort and cost are disappointing with a 75% five year mortality rate for the heart failure victims. Treatments for chronic heart failure include medical management with pharmaceutical drugs, diet and exercise, transplantation for a few lucky recipients, and mechanical assist devices, which are costly and risk failure and infection. Thus the landscape for cardiac treatment is turning in recent years to transplantation of tissue or cells.Medical researchers have transplanted human hematopoetic stem cells, mesenchymal stem cells, endothelial precursor cells, cardiac stem cells, and skeletal myoblasts or bone marrow cells to the myocardium, with however little or mixed success in satisfactory regeneration of the myocardium. Another protocol involved injecting transforming growth factor beta preprogrammed bone marrow stem cells to the myocardium, with greater success than ...

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. 1. An injectable composition for inducing angiogenesis comprising an extracellular matrix component and a supplemental bioactive component , said bioactive component comprising a fibroblast growth factor , said extracellular matrix scaffold component comprising urinary bladder submucosa (UBS).2. The composition of claim 1 , wherein said fibroblast growth factor comprises a fibroblast growth factor-2 (FGF-2).3. The composition of claim 1 , wherein said fibroblast growth factor comprises a transforming growth factor beta (TGF-beta).4. (canceled) This application is a Divisional Application of U.S. application Ser. No. 11/182,551, filed on Jul. 15, 2005.The invention relates to tissue engineering generally, and more specifically to compositions and methods for regenerating defective or absent myocardium.Heart failure occurs in nearly 5 million people a year in the U.S. alone at a combined cost of about $40 billion annually for hospitalization and treatment of these patients. The results of all the effort and cost are disappointing with a 75% five year mortality rate for the heart failure victims. Treatments for chronic heart failure include medical management with pharmaceutical drugs, diet and exercise, transplantation for a few lucky recipients, and mechanical assist devices, which are costly and risk failure and infection. Thus the landscape for cardiac treatment is turning in recent years to transplantation of tissue or cells.Medical researchers have transplanted human hematopoetic stem cells, mesenchymal stem cells, endothelial precursor cells, cardiac stem cells, and skeletal myoblasts or bone ...

CAPPING BIOPROSTHETIC TISSUE TO REDUCE CALCIFICATION

A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization. 1. A method for treating bioprosthetic tissue comprising:at least partially cross-linking the bioprosthetic tissue;capping one or both of a carboxylic acid group and an aldehyde group generated from the cross-linking of the bioprosthetic tissue; andcontacting the bioprosthetic tissue with glycerol.2. The method of claim 1 , wherein the cross-linking is performed using glutaraldehyde.3. The method of claim 2 , further comprising rinsing the bioprosthetic tissue with at least one of an ethanol or an ethane solution before the capping.4. The method of claim 1 , wherein the capping is performed by exposing the bioprosthetic tissue to one or more capping agents.5. The method of claim 4 , wherein the capping agent is selected from the group consisting of: an amine claim 4 , an alkyl amine claim 4 , an amino alcohol claim 4 , an ethanolamine claim 4 , an amino acid claim 4 , a lysine claim 4 , a hydroxylysine claim 4 , an amino sulfonate claim 4 , a taurine claim 4 , an amino sulfate claim 4 , a dextran sulfate claim 4 , a chrondoitin sulfate claim 4 , a hydrophilic multifunctional polymer claim 4 , a polyvinyl alcohol claim 4 , a polyethyleneimine claim 4 , a hydrophobic multifunctional polymer claim 4 , α-dicarbonyl claim 4 , a ...

Method and device for modelling tendinous tissue into a desired shape

The present invention relates to methods and devices for the modelling tendinous tissue into a desired shape. The shaped tissue produced by the methods of the present invention is useful in any field relating to biological tissue, particularly in the field of medicine, most preferred in surgery, for intraoperative use or pre- or peri-operative preparation of the tissue.

Bone Matrix Compositions and Methods

Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone, and optionally providing a tissue-derived extract and adding the tissue-derived extract to the partially demineralized bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract.

Biomatrix Scaffolds for Industrial Scale Dispersal

The present invention provides biomatrix scaffolds for industrial scale dispersal.

SYNTHETIC SCAFFOLDS AND ORGAN AND TISSUE TRANSPLANTATION

Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided. 1. A synthetic scaffold for replacing an airway or portion thereof comprising:one or more structural ribs on an airway mold,wherein each structural rib comprises a first material,wherein the airway mold and one or more structural ribs is coated with a second material, andwherein the second material is solidified to form a conduit that comprises the one or more structural ribs.2. The scaffold of claim 1 ,wherein the first material is a set POSS-PCU nanocomposite material orwherein the airway mold comprises a convex anterior and a straight posterior orwherein each structural rib is U-shaped orwherein the airway mold is a glass, stainless steel, or PTFE mold orwherein each structural rib is about 0.5 cm thick orwherein the structural ribs are separated by about 0.5 cms along the length of the airway mold orwherein the airway mold is a tracheal mold having a diameter of approximately 2-3 cm orwherein the airway mold is a bronchial mold having a diameter of approximately 1-1.5 cm orwherein the airway mold is branched and includes one tracheal segment and two bronchial segments orwherein the conduit is porous.3. The scaffold of claim 2 ,wherein the second material is a POSS-PCU fluid and the solidifying comprises coagulating the POSS-PCU fluid orwherein each structural rib has an internal width of about 2-3 cm orwherein each structural rib has an internal width of about 1-1.5 cm.wherein the airway mold includes a detachable bronchial segment orwherein the second material is a POSS-PCU polymer fluid that comprises salt crystals, and wherein the POSS-PCU polymer is coagulated in an aqueous solution, and wherein the salt crystals are dissolved after coagulation to form pores orwherein the average pore diameter is 20-100 microns.4. The scaffold of claim 3 , ...

TISSUE IMPLANTS FOR IMPLANTATION AND METHODS OF PREPARING THE SAME

A method is provided for preparing a tissue implant for implantation. The method includes harvesting a tissue material from a human or an animal donor, treating the tissue material in a nuclease-containing solution, and thereafter treating the tissue material with an alkaline alcohol solution. The nuclease-containing solution includes an antimicrobial. The alkaline alcohol solution comprises sodium hydroxide and ethanol. 1. A method of preparing a tissue implant for implantation comprising:treating a decellularized tissue material with an alkaline alcohol solution,wherein the tissue material comprises mammalian pericardium.2. The method of claim 1 , wherein the alkaline alcohol solution comprises ethanol.3. The method of claim 2 , wherein the ethanol is present in a concentration of about 72 to about 88 percent v/v.4. The method of claim 1 , wherein the alkaline alcohol solution comprises a hydroxide salt.5. The method of claim 4 , wherein the hydroxide salt comprises sodium hydroxide.6. The method of claim 5 , wherein the alkaline alcohol solution is about 0.016 M to about 0.022 M sodium hydroxide.7. The method of claim 1 , wherein the alkaline alcohol solution comprises ethanol in a concentration from about 72 to about 88 percent v/v and about 0.016 M to about 0.022 M sodium hydroxide.8. The method of claim 1 , wherein the decellularized tissue material is treated with the alkaline alcohol solution for about 60 minutes to about 3 hours.9. The method of claim 1 , wherein the tissue material comprises human claim 1 , bovine claim 1 , or equine pericardium.10. A method of preparing a tissue implant for implantation comprising:treating a decellularized tissue material with an alkaline alcohol solution; andtreating the tissue material with a chlorine dioxide solution.11. The method of claim 10 , wherein the alkaline alcohol solution comprises ethanol.12. The method of claim 11 , wherein the ethanol is present in a concentration of about 72 to about 88 percent v/v.13. ...

Muscle-based grafts/implants

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic agent to attract a desired cell.

BIODEGRADABLE TISSUE COMPOSITION WITH BIODEGRADABLE CROSS-LINKERS

Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed. 1. A biodegradable bioprosthesis comprising:a first biodegradable tissue portion;a second biodegradable tissue portion; andone or more biodegradable crosslinkers crosslinking the first biodegradable tissue portion with the second biodegradable tissue portion.2. The bioprosthesis of claim 1 , wherein the first biodegradable tissue portion and/or the second biodegradable tissue portion includes animal tissue.3. The bioprosthesis of claim 1 , wherein the one or more biodegradable crosslinkers degrade by hydrolysis or enzyme.4. The bioprosthesis of claim 3 , wherein the first biodegradable tissue portion and/or the second biodegradable tissue portion becomes susceptible to enzymatic degradation upon degradation of the one or more biodegradable corsslinkers.5. The bioprosthesis of claim 4 , wherein the wherein the first biodegradable tissue portion and/or the second biodegradable tissue portion degrades into non-toxic components.6. The bioprosthesis of claim 1 , wherein the one ...

Extracellular Matrix-Derived Gels and Related Methods

Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient. 196-. (canceled)97. A method of preparing an extracellular matrix-derived gel comprising: (a) solubilizing decellularized extracellular matrix (ECM) derived from cardiac tissue by digestion with an acid protease in an acidic solution to produce digested cardiac ECM; and (b) raising the pH of the digested cardiac ECM to a pH between 7.2 and 7.8 to produce a neutralized digest solution , and (c) gelling the neutralized digest solution at a temperature greater than 25° C.98. The method of claim 97 , wherein the ECM is not dialyzed or subjected to a cross-linking process prior to the gelling step (c).99. The method of claim 97 , wherein the ECM is intact ECM.100. The method of claim 97 , wherein the neutralized digest solution is maintained at or below 25° C. before the gelling step (c).101. The method of claim 97 , wherein the protease is pepsin claim 97 , trypsin or a combination thereof.102. The method of claim 97 , wherein in the step of raising the pH of the digested cardiac ECM (b) claim 97 , a base or an isotonic buffer is added to raise the pH of the digested cardiac ECM.103. The method of claim 102 , wherein the base or isotonic buffer is NaOH or phosphate buffered saline.104. The method of claim 97 , wherein the pH is raised to 7.4 in the step of raising the pH of the digested cardiac ECM (b).105. The method of claim 97 , wherein the digest solution is gelled at 30° C. or higher.106. The method of claim 97 , wherein the digest solution is gelled at 37° C.107. The method of ...

PLATFORM FOR ENGINEERED IMPLANTABLE TISSUES AND ORGANS AND METHODS OF MAKING THE SAME

Disclosed are engineered tissues and organs comprising one or more muscle cell-containing layers, the engineered tissue or organ consisting essentially of cellular material, provided that the engineered tissue or organ is implantable in a vertebrate subject and not a vascular tube. 1. A living , three-dimensional engineered tissue or organ comprising one or more layers , the one or more layers characterized by one or more of: a) substantially scaffold-free at the time of use; and b) bioprinted , the one or more layers suitable for implantation in a vertebrate subject upon sufficient maturation; provided that at least one layer of the engineered tissue or organ comprises muscle cells and that the engineered tissue or organ is not a vascular tube.2. The tissue or organ of claim 1 , wherein at least one layer comprises a plurality of cell types claim 1 , the cell types spatially arranged relative to each other to create a planar geometry.3. The tissue or organ of claim 2 , wherein at least one layer is at least 100 μm thick in its smallest dimension at the time of fabrication.4. The tissue or organ of claim 1 , comprising a plurality of layers claim 1 , at least one layer compositionally or architecturally distinct from at least one other layer to create a laminar geometry.5. The tissue or organ of claim 4 , wherein at least one layer is at least 100 μm thick in its smallest dimension at the time of fabrication.6. The tissue or organ of claim 1 , wherein the tissue or organ is a sac claim 1 , sheet claim 1 , or tube claim 1 , wherein said tube is not a vascular tube.7. The tissue or organ of claim 1 , wherein the tissue or organ is substantially free of any pre-formed scaffold at the time of use.8. The tissue or organ of claim 1 , wherein the tissue or organ is bioprinted.9. The tissue or organ of claim 1 , wherein the one or more layers generates an extracellular matrix.10. The tissue or organ of claim 1 , wherein the muscle cells are smooth muscle cells.11. The ...

Unitary Endoscopic Vessel Harvesting Devices

Unitary surgical devices are disclosed. Such devices may include an elongated body extending between a proximal end and a distal end, and having one or more lumens extending through the elongated body and a tip disposed at the distal end of the elongated body. The harvesting device may further include a first gripping element disposed about the dissection tip and a second gripping element disposed about the dissection tip distally of the first gripping member. The second gripping member may be moveable with respect to the first gripping member for capturing a blood vessel between the first gripping member and the second gripping member. The blood vessel captured between first gripping member and the second gripping member may then be sealed and, subsequently, severed by a cauterizing element disposed between the first gripping member and the second gripping member. 1. An surgical device comprising:an elongated body extending between a proximal end and a distal end, and having one or more lumens extending through the elongated body;a tip disposed at the distal end of the elongated body;a first gripping element disposed about the dissection tip;a second gripping element disposed about the dissection tip distally of the first gripping member, the second gripping member being moveable with respect to the first gripping member between an open position away from the first gripping member to a closed position toward the first gripping member for gripping a blood vessel between the first gripping member and the second gripping member; anda cauterizing element disposed between the first gripping member and the second gripping member such that the blood vessel, when gripped between the first gripping member and the second gripping member, is pressed against the cauterizing element for sealing the blood vessel.2. The device of wherein the cauterizing element is further used to sever the blood vessel.3. The device of further comprising controls disposed near the proximal end of ...

Multilayered silk scaffolds for meniscus tissue engineering

Provided herein is a biocompatible implant for meniscus tissue engineering. Particularly, the biocompatible implant comprises a multi-layered crescent-shaped silk fibroin scaffold, in which each layer comprises distinct pore size and/or pore orientation, e.g., to mimic native meniscus complex architecture. Accordingly, the biocompatible implant can be used for repairing any meniscal defect or promoting meniscal regeneration in a subject.

Prosthetic heart valve including stent structure and tissue leaflets, and related methods

A method of making a prosthetic heart valve may include providing an annular stent having a plurality of annularly spaced commissure portions having tips, covering each of the tips with a first fabric cover, covering the first fabric covers and the remainder of the stent with a second fabric cover, covering the second fabric cover with a first tissue membrane, and covering the outside of the first tissue membrane with a second tissue membrane, the second tissue membrane forming leaflet portions that extend inwardly between the commissure portions.

Light-Activated Cation Channel and Uses Thereof

The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.

CROSS-LINKED BIOACTIVE HYDROGEL MATRICES

The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking. 1. A bone implant material formed of a molded composition having a predetermined shape and comprising: a crosslinked bioactive hydrogel matrix comprising a polyglycan crosslinked to a polypeptide , and at least one enhancing agent selected from the group consisting of polar amino acids , intact collagen , divalent cation chelators , and combinations thereof; and an osteoinductive or osteoconductive material comprising hydroxyapatite.2. The bone implant material of claim 1 , wherein the polyglycan is a polysaccharide or a sulfated polysaccharide.3. The bone implant material of claim 2 , wherein the polyglycan is selected from the group consisting of glycosaminoglycans claim 2 , glucosaminoglycans claim 2 , dextran claim 2 , heparan claim 2 , heparin claim 2 , hyaluronic acid claim 2 , alginate claim 2 , agarose claim 2 , carageenan claim 2 , amylopectin claim 2 , amylose claim 2 , glycogen claim 2 , starch claim 2 , cellulose claim 2 , chitin claim 2 , heparan sulfate claim ...

PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. 1. A tissue graft comprising a first membrane comprising an amnion and one or more additional membranes laminated to the first membrane , wherein the first membrane comprises an exposed basement membrane and stromal layer , and the one or more additional membranes are adjacent to the stromal layer.234-. (canceled) This application is a continuation application of U.S. application Ser. No. 13/569,134, filed on Aug. 7, 2012; which is a continuation application of U.S. application Ser. No. 12/428,908, filed on Apr. 23, 2009, now U.S. Pat. No. 8,323,701, issued on Dec. 4, 2012; which is a continuation application of U.S. application Ser. No. 12/206,508, filed on Sep. 8, 2008, now U.S. Pat. No. 8,357,403, issued on Jan. 22, 2013; which claims priority upon U.S. provisional application Ser. Nos. 60/970,780, filed September 7, 2007; 60/986,665, filed Nov. 9, 2007; and 60/989,299, filed Nov. 20, 2007. Each application is hereby incorporated by reference in its entirety for all of its teachings.Human placental membrane (e.g. amniotic membrane or tissue) has been used for various types of reconstructive surgical procedures since the early 1900s. The membrane serves as a substrate material, more commonly ...

XENOGRAFT SOFT TISSUE IMPLANTS AND METHODS OF MAKING

The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes. 1. A method for the preparation of a graft from animal dermis comprising the following steps:a. providing an animal dermis,b. treating the animal dermis with an aqueous sodium sulfide solution,c. once or several times, treating the dermis with an aqueous salt solution,d. once or several times, treating the dermis with an aqueous hydrogen peroxide solution, ande. dehydrating the dermis.2. The method of claim 1 , wherein in step b an aqueous alkaline claim 1 , sodium sulfide-containing solution is used.3. The method of claim 1 , wherein in step b an aqueous solution is used which contains from 0.01 to 10 weight-% of sodium sulfide.4. The method of claim 1 , wherein in said step b claim 1 , an aqueous solution is used which in addition to sodium sulfide contains 0.001 to 0.5 M sodium hydroxide.5. The method of claim 1 , wherein said dermis in step b) is treated in an aqueous sodium sulfide containing solution for 1 to 48 hours claim 1 , with a solution volume in milliliters that is 5 to 15 times the mass of the dermis in grams.6. The method of claim 1 , wherein said dermis in step c) is treated two to ten times with an aqueous claim 1 , 1 to 50 wt-% salt solution claim 1 , wherein the salt is an alkali metal or alkaline earth metal claim 1 , selected from the group consisting of sodium chloride claim 1 , potassium chloride claim 1 , lithium ...

Method for Producing a Bone Transplant Material, and Bone Transplant Material Produced by Same

The present invention relates to a method for producing a bone transplant material using an extracted tooth, and to a bone transplant material produced by same, and particularly, to a method for producing a bone transplant material which enables the production of bone transplant material in a short amount of time using an extracted tooth of a patient or a similar tooth. 1. A method for producing a bone transplant material , comprising:using a chemical reagent to execute at least one chemical treatment of at least one hard body tissue selected from extracted teeth and bones,wherein the at least one chemical treatment using a chemical reagent is accompanied with sonication including vacuum sonication that provide irradiation by ultrasonic waves at a reduced pressure.2. The method according to claim 1 , wherein the sonication is conducted at an ultrasonic frequency ranging from 15 kHz to 40 kHz.3. The method according to claim 1 , wherein the vacuum sonication is conducted at a vacuum pressure ranging from 10 mmHg (torr) to 700 mmHg (torr).4. (canceled)5. The method according to any one of claim 1 , wherein the sonication comprises vacuum sonication to irradiate ultrasonic waves at a reduced pressure claim 1 , non-vacuum sonication to irradiate ultrasonic waves without a reduced pressure condition claim 1 , and further vacuum sonication to irradiate ultrasonic waves at a reduced pressure claim 1 , in consecutive order.6. The method according to claim 1 , wherein the at least one chemical treatment is conducted in a range of room temperature to 60° C.7. The method according to claim 1 , further comprising a treatment using distilled water for purposes other than washing claim 1 , wherein the treatment using distilled water is accompanied with sonication.8. The method according to claim 1 , further comprising:{'b': '1', 'removing and washing soft tissues and tooth pulp of the extracted tooth (step S);'}{'b': 1', '2, 'separating a tooth crown and tooth root from the tooth ...

Enzyme-activated collagen and tissue matrices

Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.

Amnion and chorion constructs and uses thereof in ob-gyn surgery

A construct for use in an OB/GYN surgery is described. The construct contains an allograft having at least one layer of human amnion and chorion tissues, and has a size and shape appropriate for covering an incision or a surgical site resulting from the surgery. Methods of preparing the construct and using it in an OB/GYN surgery are also described. The products and methods improve the performance of the OB/GYN surgery, e.g., by reducing adhesions, scar formation while also reducing inflammation and risk of post-operative infection.

COMPOSITIONS AND METHODS FOR AUGMENTATION AND REGENERATION OF LIVING TISSUE IN A SUBJECT

The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive. 150-. (canceled)51. A method for treating incontinence comprising regeneration or augmentation of sphincter muscle tissue in a patient by the steps ofobtaining a composition comprising a population of porous microparticles of biodegradable polymer and a population of myoblasts andadministering the composition to sphincter muscle tissue of a patient in need thereof.52. The method according to claim 51 , wherein administering the composition is by injection.53. The method according to claim 51 , wherein the porous microparticles have a porosity of 50 to 95%.54. The method according to claim 51 , wherein the porous microparticles have a size of 20-110 μm.55. The method according to claim 51 , wherein the composition further comprises one or more mammalian cell populations.56. The method according to claim 51 , wherein the composition further comprises a biocompatible adhesive.57. The composition according to claim 51 , wherein the composition further comprises one or more mammalian cell populations attached to the population of porous microparticles.58. The method according to claim 51 , wherein the porous microparticles are microspheres.59. The method according to claim 51 , wherein the porous microparticles have irregular shapes claim 51 , such as flakes of the biodegradable polymer.60. The method according to claim 51 , wherein the porous microparticles are flake shaped.61. The method according to claim 51 , wherein the biodegradable polymer is selected from the group consisting ofa) homopolymers and copolymers of glycolide, such as L-lactide, DL-lactide, meso-lactide (polylactide, PLA), e-caprolactone (polycapro lactone, PCL), 1,4-dioxane-2-one, d-valerolactone, β-butyrolactone, g-butyrolactone, ...

Method for producing implant material

The production method of an implant material of the present invention includes step (A): a step of setting a porous ceramic material having substantially unidirectionally arrayed pores at any depth position inside a container, step (B): a step of filling the container with a cell-containing liquid containing at least bone marrow blood and/or peripheral blood, and step (C): a step of applying, on the container, a centrifugal force in the direction along the axis of the container.

CARRIER MATERIAL FOR BONE FORMING CELLS

The present invention relates to a carrier material and bone forming cells, which material is capable of providing treating orthopaedic conditions. In particular, the present invention relates to a bone forming carrier material comprising an anti-inflammatory amount of allogenic bone gel and a bone forming amount of bone-forming cells. 1. (canceled)2. A bone forming carrier material comprising allogenic bone gel and a bone forming amount of bone forming cells , wherein the gel provides at least a 3 fold reduction in the number of polymorphonuclear leukocytes in a subject's tissue.3. The bone forming carrier material of claim 2 , wherein said bone-forming cells are selected from the group consisting of osteoblasts claim 2 , mesenchymal stem cells and progenitor cells or combinations thereof.4. The bone forming carrier material of claim 2 , wherein said bone-forming cells are autologous cells.5. The bone forming carrier material of claim 2 , wherein the bone-forming cells are purified or substantially purified cells that express one or more genes selected from the group consisting of collagen type I claim 2 , osteopontin and osteocalcin.6. The bone forming carrier material of claim 2 , wherein the bone-forming cells are purified or substantially purified osteoblasts.7. The bone forming carrier material of claim 2 , wherein said bone-forming cells comprise about 10-10bone forming cells.8. A medical device coated with the bone forming carrier material of .9. A method of treating an orthopeadic condition comprising the step of administering the bone forming carrier material of .10. A method of inducing bone formation in vivo comprising the steps of:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a. providing the bone forming carrier material of ; and'}b. applying said carrier material to a site requiring new bone formation.11. A method of treating an orthopeadic condition comprising the step of administering the medical device of . The present invention relates to ...

Systems for cartilage repair

Neo-cartilage constructs suitable for implantation into a joint cartilage lesion in situ and a method for repair and restoration of function of injured, traumatized, aged or diseased cartilage. The construct comprises at least chondrocytes incorporated into a support matrix processed according to the algorithm comprising variable hydrostatic or atmospheric pressure or non-pressure conditions, variable rate of perfusion, variable medium composition, variable temperature, variable cell density and variable time to which the chondrocytes are subjected.

Controlled Release Combination Biomaterials

In one aspect, the invention relates to tissue graft combination biomaterials capable of controlled release of bioactive agents or pharmaceutically active agents through a rate-controlling polymer coating encapsulating the graft material, methods for preparing same, methods of controlled release using same, and methods for treating tissue defects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. 1. A combination biomaterial comprising a mixture of (i) a substrate that is not collagen and (ii) a degradable polymer admixed with an agent that is bioactive or pharmaceutically active , wherein (a) the degradable polymer has a structure and a molecular weight selected to degrade over a time period when implanted within a subject so as to release the agent over the time period and (b) the substrate is a predominant component of the combination biomaterial.2. The combination biomaterial of claim 1 , wherein the degradable polymer has a structure and a molecular weight selected to degrade over a time period when implanted within a subject so as to release the agent in a therapeutically effective amount.3. The combination biomaterial of claim 1 , wherein the time period is greater than four weeks.4. The combination biomaterial of claim 1 , wherein the time period is greater than six weeks.5. The combination biomaterial of claim 1 , wherein the time period of greater than eight weeks.6. The combination biomaterial of claim 1 , wherein the release is a sustained release or an intermittent release.7. The combination biomaterial of claim 1 , wherein the substrate is selected from the group consisting of an autograft bone material claim 1 , an alloplastic material claim 1 , an allograft bone material claim 1 , a demineralized bone matrix (DBM) claim 1 , a xenograft bone fragment claim 1 , a calcium phosphate claim 1 , a calcium sulfate claim 1 , a calcium hydroxyphosphate claim ...

Method for modifying the wettability and other biocompatibility characteristics of a surface of a biological material by the application of beam technology and biological materials made thereby

A method of preparing a preformed bone shape for implantation provides irradiating at least a portion of a preformed bone shape by a Neutral Beam derived from a GCIB, and the preformed bone shape so irradiated.

Flowable matrix compositions and methods

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

RADIATION CROSS-LINKED COLLAGEN GEL, AND PREPARATION METHOD AND USAGE METHOD THEREOF

The present invention relates to radiation cross-linked collagen gel, and a preparation method and usage method thereof. To this end, the present invention comprises a cross-linked collagen material made by irradiating liquid collagen with radioactive rays, wherein the concentration of said collagen is specifically 0.1-10% (W/V), and the radiation dose (dose rate×time) is 0.1-40 kGy on the basis of 1 kGy/hr. The present invention configured as above can prepare a formulated collagen gel using a physical cross-linking method instead of a chemical cross-linking method, specifically carries out the formulation by mixing biocompatible materials, and provides a method capable of using a cross-linked collagen hydrogel in wound dressings, graft materials, cell cultures and the like. Therefore, the present invention provides an industrially convenient and safe preparation method, thereby instilling a good image to a customer by greatly improving the quality and confidence in the products. 1. A method for preparing a radiation-crosslinked collagen gel , the method comprising irradiating liquid collagen with radiation to prepare a crosslinked collagen.2. The method of claim 1 , wherein the radiation is any one selected from among gamma-rays claim 1 , electron rays and X-rays.3. The method of claim 1 , wherein the concentration of the collagen in the liquid collagen is 0.1-10% (W/V) claim 1 , and the dose (dose rate×time) of the radiation is 0.1-40 kGy/hr.4. The method of claim 1 , wherein the method comprises mixing 3% (W/V) of collagen with each of 3% (W/V) of synthetic polymer Pluronic F-127 claim 1 , 1% (W/V) of PEO (polyethylene oxide (M.W.=100 claim 1 ,000) and 3% (W/V) of hydroxyapatite and crosslinking the mixture by irradiation with gamma-rays.5. The method of claim 1 , wherein the method comprises mixing 3% (W/V) of collagen with each of 3% (W/V) of biopolymer hyaluronic acid (M.W.=2 claim 1 ,000 K) and 3% (W/V) of chondroitin sulfate and crosslinking the mixture by ...

Multilayered implant materials derived from amniotic membrane, methods of making the multilayered implant materials, and method of using multilayered implant materials

Exemplary embodiments of the present disclosure provide for multi-layered implantation materials, methods of making a multi-layered implantation material, methods of forming a multi-layered implantation material, methods of forming a multi-layered implantation material having a spiral roll cross-section, and the like.

XENOGRAFT SOFT TISSUE IMPLANTS AND METHODS OF MAKING AND USING

The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that neutralizes, removes or substantially reduces antigens from and sterilizes and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as tendons and ligaments, and to implants produced by such processes. 1. A xenograft tendon implant comprising xenograft tendon treated with a sugar solution that exhibits enhanced post-surgical healing and/or strength as compared to either a comparable allograft or autograft implant.2. The implant of claim 1 , wherein the implant is of bovine origin.3. The implant of claim 2 , wherein the implant is taken from a santa gertrudis cow.4. The implant of claim 1 , wherein the implant comprises an anterior extensor tendon.5. The implant of claim 4 , wherein the implant comprises an Extensor Digitorum Medialis.6. The implant of claim 1 , wherein the implant exhibits a pH of about 8 prior to implantation.7. The implant of claim 1 , wherein the sugar is selected from glucose claim 1 , dextrose claim 1 , cerelose claim 1 , aldose claim 1 , ketose claim 1 , hemiacetal claim 1 , pyranose claim 1 , furanose claim 1 , erythrose claim 1 , threose claim 1 , ribose claim 1 , arabinose claim 1 , mannose claim 1 , allose claim 1 , altrose claim 1 , xylose claim 1 , lyxose claim 1 , gulose claim 1 , idose claim 1 , galactose claim 1 , talose claim 1 , sucrose and fructose.8. The implant of claim 1 , wherein the implant exhibits a controlled reduction in at least one xenoantigen of about 60% claim 1 , a trypsin digestion less than about 10% claim 1 , and predicted UTF ...

Methods of conditioning sheet bioprosthetic tissue

Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.

Method of Demineralizing Bone

The invention is directed to an apparatus for producing demineralized osteoinductive bone. The apparatus demineralizes bone by subjecting bone, including, for example, ground bone, bone cubes, chips, strips, or essentially intact bone, to either a rapid high volume pulsatile acidification wave process or to a rapid continuous acid demineralization process. The pulsatile acidification wave process includes subjecting bone to two or more rapid pulse/drain cycles in which one or more demineralizing acids is rapidly pulsed into a vessel containing bone, and after a desired period of time, is rapidly drained from the vessel. The continuous acid demineralization process includes subjecting bone to a continuous exchange of demineralizing acid solution in which the demineralizing acid solution is recirculated from the container holding the bone through an ion exchange media. Calcium and phosphate are thereby removed from the bone to produce a regenerated acid, and the regenerated acid is returned to the container holding the bone. Both processes allow bone to be rapidly demineralized to a precise and specific desired residual calcium level without sacrificing osteoinductivity. 122-. (canceled)23. A method of demineralizing bone comprising:obtaining a bone,determining an initial calcium concentration of the bone,demineralizing the bone in an eluent acid solution in a closed reaction container,preparing a standard correlation between pH values of the eluent acid solution and residual calcium levels of the bone,determining a residual calcium level of the bone by measuring a pH value of the eluent acid solution and using the standard correlation, andstopping the demineralization of the bone sample.24. The method according to claim 23 , wherein the preparing the standard correlation step comprises:periodically sampling the eluent acid solution and the bone simultaneously with the demineralizing step,determining a pH value of the each sampled eluent acid solution and a residual ...

PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. 134.-. (canceled)35. A multilayered tissue graft consisting essentially of:at least one layer of isolated dehydrated chorion tissue; andat least one layer of isolated dehydrated amnion tissue provided that at least one of said amnion layers has an exposed basement layer and an intact fibroblast component wherein at least one of the chorion layer(s) is layered directly over the fibroblast component of said amnion layer.36. The multilayered tissue graft of claim 35 , wherein each of said layers of said graft are laminated and dehydrated together.37. The multilayered tissue graft of claim 36 , wherein the tissue graft is maintained in a drying fixture during dehydration.38. The multilayered tissue graft of claim 35 , wherein the tissue graft is sterilized.39. The multilayered tissue graft of claim 35 , consisting essentially of one layer of amnion tissue and one layer of chorion tissue.40. The multilayered tissue graft of claim 35 , consisting essentially of multiple layers of amnion tissue and multiple layers of chorion tissue.41. The multilayered tissue graft of claim 35 , consisting essentially of multiple layers of amnion tissue.42. The multilayered tissue graft of claim 35 , wherein at least ...

CARTILAGE MATERIAL

Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect. 1. A cartilage composition for repairing articular cartilage defects comprises:an articular cartilage material, the material being non-demineralized and not subjected to demineralization treatments or harsh chemicals which alter the natural properties of the cartilage material, the cartilage material in the form of pieces of cartilage having been washed in normal saline washes and frozen rapidly, not having been subjected to elevated temperatures greater than 50 degrees C. is dried to about 3 to 5 percent moisture content, the pieces of cartilage material being preserved, freeze-dried, frozen or cryo-preserved cartilage; the pieces of preserved cartilage material is ground or milled or shaved intermittently without raising the temperature above 40 degrees C. to form a ground, milled or shaved material of a cartilage fluff and cartilage particles, after each grinding or milling cycle, the material is sieved through sieve openings of 850 μm and 1000 μm size allowing the cartilage particles to pass and a cartilage fluff made of a plurality of branched strands to be separated from the particles, the cartilage fluff having cohesive characteristics wherein the fluff sticks to itself to form a continuous network of cartilage fluff for packing into defects of articular cartilage or bone.2. The cartilage composition for repairing articular cartilage defects of wherein the strands have one or more branches claim 1 , the strands having an average length up to 3000 μm.3. The cartilage composition for repairing articular cartilage defects of wherein ...

Textured bone block implants

Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a 2 ) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.

NON-WOVEN FABRIC CONTAINING BONE PROSTHETIC MATERIAL

An object of the present invention is to provide a bone regeneration material suitable for bone (in particular, alveolar bone) regeneration. The present invention provides a non-woven fabric containing a bone prosthetic material wherein the bone prosthetic material is included between biocompatible fibers that constitute the non-woven fabric. The non-woven fabric may be suitably used as a bone regeneration material (in particular, a dental bone regeneration material). 1. A non-woven fabric containing a bone prosthetic material wherein the bone prosthetic material is included between biocompatible fibers that constitute the non-woven fabric.2. The non-woven fabric according to claim 1 , wherein the biocompatible fibers contain a biocompatible polymer.3. The non-woven fabric according to claim 2 , wherein the biocompatible polymer is at least one member selected from the group consisting of polylactic acid claim 2 , polyglycolic acid claim 2 , polylactic acid-polyglycolic acid copolymer claim 2 , polycaprolactone claim 2 , chitin claim 2 , collagen claim 2 , polylysine claim 2 , polyarginine claim 2 , hyaluronic acid claim 2 , sericin claim 2 , cellulose claim 2 , dextran claim 2 , and pullulan.4. The non-woven fabric according to claim 1 , wherein the bone prosthetic material is at least one member selected from the group consisting of β-TCP (β-tricalcium phosphate) claim 1 , α-TCP (α-tricalcium phosphate) claim 1 , HA (hydroxyapatite) claim 1 , DCPD (dibasic calcium phosphate dihydrate) claim 1 , OCP (octacalcium phosphate) claim 1 , 4CP (tetracalcium phosphate) claim 1 , alumina claim 1 , zirconia claim 1 , calcium aluminate (CaO—AlO) claim 1 , aluminosilicate (NaO—AlO—SiO) claim 1 , bioactive glass claim 1 , quartz claim 1 , and calcium carbonate.5. The non-woven fabric according to claim 1 , wherein the bone prosthetic material has a particle diameter of about 50 to 5000 μm.6. The non-woven fabric according to claim 1 , wherein the non-woven fabric has a porosity ...

Plant derived cell culture material

The present invention relates material that is useful in culturing and transferring cells as well as delivering cells. The material comprises plant derived cellulose nanofibers or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof.

Nanofiber scaffolds and methods for repairing skin damage

A composition is provided that includes a plurality of layered nanofiber scaffolds. A first nanofiber scaffold can include microwells configured to be seeded with one or more relevant cells, a skin tissue, or combinations thereof. Furthermore, the first nanofiber scaffold can comprise uniaxially aligned nanofibers between the microwells and random nanofibers on the microwells. The composite can also include a second nanofiber scaffold that comprises radially-aligned nanofibers. Further provided are methods for making such a composition as well as methods for treating damaged skin that include applying an effective amount of the composition to a site of damaged skin on a subject.

Bone Graft Materials Derived from Mineralized Gelatin

The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods for making DBM bone products, wherein both the DBM and a mineralized gelatin carrier for the DBM are derived independently from a bone lot. 1. A method for making a demineralized bone matrix product , comprisingseparating a bone lot into a first portion and a second portion;processing the first portion to create dried demineralized bone matrix;extracting a mineralized gelatin solution from the second portion;converting the mineralized gelatin solution to a mineralized gelatin; andcombining the dried demineralized bone matrix with the mineralized gelatin to form a demineralized bone matrix product.2. The method of claim 1 , wherein the extracting includes exposing the second portion of the bone lot to a temperature between about 40° C. and about 100° C.3. The method of claim 1 , wherein the extracting includes exposing the second portion of the bone lot to acid and sonication.4. The method of claim 1 , comprising more than one extracting step.5. The method of claim 1 , wherein the demineralized bone matrix product is in a form selected from the group consisting of a gel claim 1 , putty claim 1 , paste claim 1 , sponge claim 1 , sheet and block.6. The method of claim 1 , further comprising freeze-drying the demineralized bone matrix product.7. The method of claim 6 , further comprising re-hydrating the freeze-dried bone matrix product.8. A method for making a demineralized bone matrix product claim 6 , comprisingseparating a bone lot into a first portion and a second portion;processing the first portion to create dried demineralized bone matrix;extracting a mineralized solution from the second ...

Genetically Modified Pigs for Xenotransplantation of Vascularized Xenografts and Derivatives Thereof

The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided. 1. A transgenic animal that lacks any expression of functional alpha 1 ,3 galactosyltransferase (GTKO) and specifically expresses at least one transgene in endothelial tissue.2. The transgenic animal of claim 1 , wherein the at least one transgene is an anticoagulant.3. The transgenic animal of claim 2 , wherein the anticoagulant is thrombomodulin.4. The transgenic animal of claim 2 , wherein the anti-coagulant is selected from the group consisting of CD39 claim 2 , hirudin claim 2 , tissue factor pathway inhibitor (TFPI) claim 2 , endothelial cell protein C receptor (EPCR) and combinations thereof.5. The transgenic animal of claim 1 , wherein at least two transgenes are specifically expressed in endothelial tissue.6. The transgenic animal of claim 1 , wherein at least one transgene is an anticoagulant and at least one transgene is an immunomodulator.7. The transgenic animal of claim 6 , wherein the immunomodulator is an immunosuppressant.8. The transgenic animal of claim 7 , wherein the immunosuppressant is CTLA4 or CIITA-DN.9. The transgenic animal of claim 1 , wherein the at least one transgene is a cytoprotective transgene.10. The transgenic animal of claim 9 , wherein the cytoprotective transgene is selected from the group consisting of A20 claim 9 , HO-1 claim 9 , FAT-1 and soluble TNF-alpha receptor.11. Cells derived from the animal of .12. An organ derived from the animal of .13. Tissue ...

MICRONIZED COMPOSITIONS COMPOSED OF BONE GRAFTS AND METHODS OF MAKING AND USING THE SAME

Described herein are compositions composed of micronized particles derived from one or more components present in placental tissue in combination with one or more bone grafts. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. 1. A micronized composition comprising (a) micronized amniotic membrane , micronized amnion , micronized chorion , micronized umbilical cord , micronized umbilical cord component , micronized placental disk , or any combination thereof , and (b) one or more bone grafts.2. (canceled)3. The composition of claim 1 , wherein the micronized particles have a particle size less than 1 claim 1 ,000 μm.4. The composition of claim 1 , wherein the micronized particles have a particle size from 200 μm to 300 μm.5. The composition of claim 1 , wherein the micronized particles are 100% micronized amnion.6. The composition of claim 1 , wherein the micronized particles are 100% micronized chorion.7. The composition of claim 1 , wherein the micronized particles are micronized amnion and/or micronized chorion with micronized Wharton's jelly.8. The composition of claim 1 , wherein the bone graft is an autograft claim 1 , an allograft claim 1 , a xenograft claim 1 , an alloplast claim 1 , or any combination thereof.9. The composition of claim 1 , wherein the amount of micronized particles to bone graft is from 1:99 to 99:1 by volume.10. A pharmaceutical composition comprising the composition of and a pharmaceutically-acceptable carrier.11. The composition of claim 10 , wherein the pharmaceutically acceptable carrier comprises water claim 10 , saline claim 10 , Ringer's solution claim 10 , dextrose solution claim 10 , Hank's solution claim 10 , a buffer claim 10 , or a nonaqueous vehicle.12. The composition of claim 11 , wherein the buffer comprises a phosphate buffer claim 11 , bicarbonate buffer claim 11 , or Tris buffer.13. The composition of claim 10 , wherein the ...

METHODS OF MANUFACTURING CARTILAGE PRODUCTS

This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. 1. A method of producing a cartilage product comprising:a. providing a cartilage sample; andb. porating the cartilage sample.2. The method of claim 1 , wherein the cartilage sample comprises type II collagen claim 1 , optionally wherein the sample comprises hyaline cartilage.3. The method of claim 2 , wherein the cartilage sample has a thickness of about 0.3 mm to about 2.0 mm claim 2 , optionally wherein said thickness is about 1.0 mm to about 1.5 mm.4. The method of claim 2 , wherein the hyaline cartilage is selected from:articular cartilage, condoyle cartilage, femur condoyle cartilage, and tibial plateau cartilage.5. The method of claim 3 , wherein the cartilage sample is devoid of subchondral bone claim 3 , optionally wherein the cartilage product is devoid of a calcified cartilage layer.6. The method of claim 4 , wherein providing the cartilage sample comprises isolating the cartilage sample from subchondral bone.7. The method of claim 5 , wherein providing the cartilage sample comprises:a. isolating a sample comprising articular cartilage and subchondral bone; andb. removing the subchondral bone from the articular cartilage; andc. optionally, removing calcified cartilage from the articular cartilage.8. The method of claim 1 , wherein the cartilage sample comprises a radial layer claim 1 , a transitional layer claim 1 , and a tangential layer.9. The method of claim 8 , wherein the poration provides pores extending through:a. the radial layer;b. the transitional layer;c. the tangential layer;d. a and b; ore. a, b, and c.10. The method of claim 8 , wherein ...

Cloned biological material medical device and method thereof

A medical device, said medical device, comprises: a first component having a non-biological material; a second component having a cloned biological material, said second component being attached to said first component, wherein said first component and said second component are operatively associated in a non-living medical device for at least one of treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. In another aspect, a method comprises: preparing a cloned biological material from a tissue or an organ; attaching said biological material to a medical device; interfacing said biological material with the non-biological material; providing treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism.

POROUS BIOCERAMIC COMPOSITION FOR BONE REPAIR

The present invention relates to a porous bioceramic composition for bone repair and method of fabrication of the same. 3D-scaffolds were fabricated with a novel micro- and macro-architecture. Porous scaffolds based on dextrin, dextran, gelatin and biomineral (CaCO) powder were fabricated by heating and freeze-drying methods. Fabrication of different compositions of porous scaffolds (20, 30 wt % of gelatin, 20, 40 wt % dextrin, 30, 40, 50, 60 wt % dextran bounder with the constant quantity of CaCO50 g). The scaffolds properties were characterised by x-ray diffraction (XRD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and compression tests. 1. A method for preparation of a porous composition for 3D-scaffolds comprises the steps of:(a) dissolving gelatin, dextran and dextrin in hot deionized water,(b) stirring the mixture,(c) adding cockle shell powder to the mixture,(d) pouring the mixture into a shaped wax block,(e) drying the mixture,(f) removing the shaped wax block and obtaining a scaffold,(g) drying the scaffold2. The method of claim 1 , characterized in that prior to adding the cockle shell powder at step (c) claim 1 , the cockle shell powder is sieved at 90 μm.3. The method of characterized in that in step (a) the hot deionized water is at temperature of 70-80° C. and the step (a) is performed for 2 hours.4. The method of characterized in that in step (d) the shaped and the size of wax block is design depending on the shape and the size of the bone defect.5. The method of characterized in that step (e) is achieved by leaving the mixture over night at room temperature and pressure.6. The method of characterized in that step (f) the scaffold is dried at room temperature for 1 or 2 days then claim 1 , the scaffold is dried in an oven at 60° C. for 2 days.7. A method for preparation of a porous composition for 3D-scaffolds comprises the steps of:(a) dissolving cockle shell powder, gelatin, dextran and dextrin in hot deionized water ...

DISRUPTED CARTILAGE PRODUCTS

This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic. 1. A cartilage product comprising a disrupted collagen matrix.2. The cartilage product of claim 1 , wherein the collagen matrix comprises enzymatic disruptions.3. The cartilage product of claim 2 , wherein the collagen matrix is collagenase-digested claim 2 , optionally wherein the collagen matrix is collagenase II-digested.4. The cartilage product of claim 1 , wherein the collagen matrix comprises mechanical disruptions.5. The cartilage product of claim 4 , wherein the mechanical disruptions are partial mechanical disruptions claim 4 , wherein the collagen matrix is substantially intact.6. The cartilage product of claim 5 , wherein the mechanical disruptions are selected from: spiral cut claim 5 , grooves claim 5 , scores claim 5 , fenestrations claim 5 , and pores.7. The cartilage product of claim 4 , wherein the mechanical disruptions are full mechanical disruptions claim 4 , optionally wherein the collagen matrix minced.8. The cartilage product of claim 4 , wherein the mechanical disruptions are of the tissue-removal type.9. The cartilage product of claim 4 , wherein the mechanical disruptions are of the tissue-non-removal type.10. The cartilage product of claim 8 , wherein the mechanical disruptions extend through the entire thickness of the collagen matrix.11. The cartilage product of claim 10 , wherein the mechanical disruptions are selected from: spiral cut claim 10 , scores claim 10 , intersecting scores claim 10 , radial scores claim 10 , ...

TISSUE GRAFTING METHOD

The tissue grafting method relates to a tissue graft material, a method of preparing the material, and a method of using the material. The tissue graft material is made from the tunica serosa of the small intestine of a warm-blooded vertebrate, which has been delaminated from the tunica muscularis, tunica submucosa, and the tunica mucosa of the intestinal tissue. The tissue graft material may be perforated by discrete punctures. The tissue graft material is dehydrated by air drying or vacuum drying, sterilized with ethylene oxide, and stored in a hermetically sealed enclosure at room temperature until needed, having an indefinite storage life. When needed, the tissue graft material is rehydrated, cut to match the size of the wound, and applied to the wound. The graft may be overlaid with nylon mesh, or bandaged with an elastic tubular dressing. 1. A tissue grafting method for treating wounds on a surface area , comprising the steps of:treating a surface area requiring a skin graft with an antiseptic to produce a cleansed graft zone;cutting a tissue graft consisting of the tunica serosa from the small intestine of porcine tissue into a planar shape having a size substantially corresponding to the cleansed graft zone; andlayering the porcine tissue graft onto the cleansed graft zone to produce a dressed graft zone.2. The tissue grafting method according to claim 1 , further comprising the step of rehydrating the tissue graft prior to the step of cutting the tissue graft if the tissue graft has been stored in a dehydrated state.3. The tissue grafting method according to claim 1 , further comprising the step of covering the dressed graft zone with nylon mesh.4. The tissue grafting method according to claim 1 , further comprising the step of covering the dressed graft zone with an elastic claim 1 , tubular bandage.5. The tissue grafting method according to claim 1 , further comprising the step of exposing the dressed graft zone to light for desiccation.6. The tissue ...

Delivery Scaffolds and Related Methods of Use

The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening). 1. A scaffold composition for time-release delivery of biological or chemical agents to a subject , comprising: a) a substantially non-porous inner layer having a biological or chemical agent associated therewith; and b) porous outer layers having sufficient porosity to permit cellular ingrowth therein.2. The composition of claim 1 , wherein said substantially non-porous inner layer comprises said biological or chemical agent in encapsulated particles.3. The composition of claim 2 , wherein said encapsulated particles are microspheres.4. The composition of claim 3 , wherein said microspheres are poly(lactide-co-glycolide) microspheres.5. The composition of claim 1 , wherein said biological or chemical agent is a protein.6. The composition of claim 1 , wherein said biological or chemical agent is a cell.7. The composition of claim 1 , wherein said biological or chemical agents comprise exendin-4 and extracellular matrix proteins.8. The composition of claim 7 , further comprising pancreatic islet cells.9. The composition of claim 1 , wherein said inner layer is non-porous.10. The composition of claim 1 , wherein said inner layer is substantially free of salt.11. The composition of claim 1 , wherein said biological or chemical agent is nucleic acid.12. The composition of claim 1 , wherein said inner layer is composed of two or more different polymers.13. The composition of claim 1 , wherein said inner layer comprises two or more different biological or ...

Method for Producing an Implantable Bone Composition

Methods for producing implantable bone compositions suitable for attaching stem cells thereto, characterized in that bone particles are contacted with an albumin comprising solution. Said bone particles can be mineralized and/or lyophilized bone particles of animal or human origin. Preferably the non-immunogenic albumin comprising solution is lyophilized onto said bone particles. The invention further concerns bone compositions suitable for usin in graft implantation obtainable by said methods.

Placental tissue grafts modified with a cross-linking agent and methods of making and using the same

Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of chorion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

Synthetic scaffolds and organ and tissue transplantation

Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided.

Process for Devitalizing Soft-Tissue Engineered Medical Implants and Devitalized Soft-Tissue Medical Implants Produced

The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. 1. A process for preparing an acellular soft tissue graft for implantation into a mammalian system , comprising:extracting a soft tissue sample with an extracting solution comprising one or more nonionic detergents and one or more endonucleases, to produce extracted tissue;treating said extracted tissue with a treating solution comprising one or more anionic detergents, to produce a treated tissue;washing said treated tissue with a decontaminating solution comprising one or more decontaminating agents to produce said acellular soft tissue graft; andstoring said acellular soft tissue graft in a storage solution comprising one or more decontaminating agents.2. A process for preparing commercializable quantities of acellular soft tissue grafts for implantation into mammalian systems , comprising:obtaining tissue samples from an acceptable donor; extracting said tissue samples with an extracting solution comprising one or more nonionic detergents and one or more endonucleases, to produce extracted tissue;treating said extracted tissue with a treating solution comprising one or more anionic detergents, to produce a treated tissue;washing said treated tissue with a decontaminating solution comprising one or more decontaminating agents; to produce said acellular soft tissue graft; andstoring said acellular soft tissue graft in a storage solution comprising one or more decontaminating agents.3. A process for preparing an acellular soft ...

Method and System for Treatment of Biological Tissue

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.

Compositions, Structures and Methods for Neural Regeneration

A nerve regeneration device comprising a support structure having an outer surface and a plurality of conduits extending therethrough, the support structure comprising a first extracellular matrix (ECM) material from a mammalian tissue source, the support structure outer layer including at least a first layer comprising a first ECM composition having at least a second ECM material from a mammalian tissue source. When the nerve regeneration device is deployed proximate damaged neural tissue, the device induces modulated healing of the damaged tissue. 1. A nerve regeneration device , comprising:a support structure having an outer surface and a plurality of conduits extending therethrough, said support structure comprising a first extracellular matrix (ECM) material from a mammalian tissue source,said support structure outer layer including at least a first layer comprising a first ECM composition, said first ECM composition including at least a second ECM material from a mammalian tissue source,wherein, when said nerve regeneration device is deployed proximate damaged neural tissue, said nerve regeneration device induces modulated healing of said damaged tissue.2. The nerve regeneration device of claim 1 , wherein said first ECM composition layer comprises a first ECM composition coating.3. The nerve regeneration device of claim 1 , wherein said first ECM composition layer comprises a first ECM composition sheet member.4. The nerve regeneration device of claim 2 , wherein said support structure outer layer includes a second ECM composition layer claim 2 , said second ECM composition layer comprising said first ECM composition.5. The nerve regeneration device of claim 4 , wherein said second ECM composition layer comprises a second ECM composition coating.6. The nerve regeneration device of claim 4 , wherein said second ECM composition layer comprises a second ECM composition sheet member.7. The nerve regeneration device of claim 1 , wherein said first ECM material is ...

HYDRATION MEDIA FOR BIOLOGICAL TISSUE PRODUCTS, METHODS OF MAKING THE SAME AND METHODS OF USING

A hydration media for biological tissue products, methods of making the same and methods of using the same is provided. The hydration media includes sodium phosphate and calcium silicate and can be used to store or hydrate a biological tissue product. 1. A hydration medium for hydrating or storing at least one biological tissue , comprising: a sodium phosphate;', 'a calcium silicate; and', 'water, wherein the hydration media comprises an osmolality of about 200-about 400 milliosmoles per kilogram., 'a solution comprising2. The hydration medium of claim 1 , wherein the calcium silicate component is present at a concentration of about 0.025-about 0.100 milligrams per milliliter.3. The hydration medium of claim 1 , further comprising at least one of a potassium claim 1 , a chloride claim 1 , and a magnesium.4. The hydration medium of claim 1 , wherein a pH of the hydration media is between 7.0 and 7.7.5. The hydration medium of claim 1 , further comprising at least one additional solvent comprising an ethanol claim 1 , a dimethylsulfoxide claim 1 , or a glycerol.6. The hydration medium of claim 1 , wherein the at least one biological tissue is selected from the group comprising an allogeneic claim 1 , an autogeneic claim 1 , a xenogeneic claim 1 , and combinations thereof.7. The hydration medium of claim 1 , wherein the at least one biological tissue is selected from the group consisting of a bone claim 1 , a connective tissue claim 1 , a tendon claim 1 , a pericardium claim 1 , a dermis claim 1 , a cornea claim 1 , a dura mater claim 1 , a fascia claim 1 , a heart valve claim 1 , a ligament claim 1 , a capsular graft claim 1 , a cartilage claim 1 , a collagen claim 1 , a nerve claim 1 , a placental tissue claim 1 , and combinations thereof.8. The hydration medium for biological tissue of claim 7 , wherein the biological tissue is the bone.9. The hydration medium of claim 8 , wherein the bone is selected from the group consisting of a cortical bone claim 8 , a ...

A DEGRADABLE COMPLEX OF SYTHETIC POLYMER AND NATURAL EXTRACELLULAR MATRIX FOR VASCULAR GRAFTS WITH RELATED PREPARATION METHODS

The invention relates to the complex of synthetic polymer and natural extracellular matrix for vascular grafts and their preparation methods. The components of biodegradable synthetic polymer in the preparation process can be chosen with different material proportions. The scaffolds with different fiber diameters, different fiber arrangements, different pore sizes and different pore structures can be prepared by electro-spinning, wet-spinning, melt-spinning, 3D printing, pouring, phase separation, particle leaching and other technologies. Among them, the natural extracellular matrix components come from a wide range of sources such as vascular tissues from different kinds of animals including arteries and veins of pigs and cattle or vascular tissues from human donors including umbilical cord vessels, etc. And its composition and content can be flexibly adjusted according to the demand. The composites and artificial vessels prepared by this technology not only have good mechanical properties, controllable spatial structure and suitable degradation rate, but also have excellent biocompatibility and bioactivity. The preparation process of the invention is simple, the controllability is high, the preparation condition is mild, and is suitable for large-scale industrial production. 1. A degradable synthetic polymer and natural extracellular matrix complex material involving one portion of extracellular matrix (ECM) and 0.1-10 portion of synthetic polymer by mass fraction.2. The degradable synthetic polymers and natural extracellular matrix complex material of claim 1 , wherein the synthetic polymers is consist of one or more of the following materials: polycaprolactone (PCL) claim 1 , poly (lactide caprolactone) copolymer (PLCL) claim 1 , polyurethane (PU) claim 1 , polyglycerol sebacate (PGS) claim 1 , poly (p-dioxane) (PDS) claim 1 , polyglycolic acid (PGA) claim 1 , poly (lactide)(PLA) claim 1 , poly (lactide glycolic acid) copolymer (PLGA) claim 1 , polyhydroxy fatty ...

IMPLANTABLE MESH

An implantable mesh including demineralized bone fibers mechanically entangled into a biodegradable or permanent implantable mesh is provided. A method of preparing the implantable mesh is also provided. The method of preparing the implantable mesh includes mechanically entangling demineralized bone fibers with non-bone fibers to form the implantable mesh. The mechanical entanglement of the bone fibers into the implantable mesh is achieved by applying needle punching with barbed needles, spun lacing, entanglement with water jets or air jets or ultrasonic entanglement with ultrasonic waves. A method of implanting an implantable mesh at a target bone tissue site is also provided. 111-. (canceled)12. A method of preparing an implantable mesh , the method comprising mechanically entangling demineralized bone fibers with non-bone fibers to form the implantable mesh.13. A method of claim 12 , wherein the mechanical entangling comprises applying needle punching with barbed needles claim 12 , spun lacing claim 12 , entanglement with water jets or air jets or ultrasonic entanglement with ultrasonic waves.14. A method of claim 13 , wherein the mechanical entangling further comprises applying to the implantable mesh moisture claim 13 , heat and/or pressure provided by pressure rollers.15. A method of claim 12 , wherein (i) the mesh is porous having pores from about 100 to about 200 μm; (ii) the mesh does not contain a carrier; or (iii) the mesh is woven claim 12 , non-woven claim 12 , knitted claim 12 , wrapped claim 12 , plied claim 12 , braided or a mixture thereof.16. A method of claim 12 , wherein the demineralized bone fibers have (i) an aspect ratio of from about 50:1 to about 1000:1; (ii) a diameter from about 100 μm to about 2 mm; or (ii) a length from about 0.5 cm to about 10 cm.17. A method of implanting an implantable mesh at a target bone tissue site claim 12 , the method comprising contacting the bone tissue site with the implantable mesh claim 12 , the ...

TISSUE AUGMENTATION SCAFFOLDS FOR USE IN SOFT TISSUE FIXATION REPAIR

Devices, systems, and methods to improve both the reliability of soft tissue repair procedures and the speed at which the procedures are completed are provided. The devices and systems include one or more tissue augmentation constructs, which include constructs that are configured to increase a footprint across which suture applied force to tissue when the suture is tied down onto the tissue. The tissue augmentation constructs can be quickly and easily associated with the repair suture, and can be useful in many different tissue repair procedures that are disclosed in the application. Tissue augmentation constructs can include various blocks and scaffolds, among other formations. The present disclosure includes, among other disclosures, methods for using tissue augmentation scaffolds, including folding scaffolds, and descriptions and methods associated with extra-wide tissue augmentation blocks. 1. A method of soft tissue repair , comprising:passing a first suture through soft tissue from a medial suture anchor disposed in bone at a surgical repair site below the soft tissue such that a first suture limb and a second suture limb of the first suture extends from the soft tissue;passing a second suture from the medial suture anchor through the soft tissue such that a first suture limb and a second suture limb of the second suture extends from the soft tissue;installing a medial row stitch on the second suture to secure the soft tissue to the bone;threading the first suture limb of the first suture through a channel in a tissue augmentation scaffold;delivering the tissue augmentation scaffold to the surgical repair site;coupling the first suture limb of the first suture to a first lateral suture anchor disposed in bone after the tissue augmentation scaffold has been delivered to the surgical repair site; andpassing the second suture limb of the first suture across a top face of the tissue augmentation scaffold, after the tissue augmentation scaffold has already been ...

DEMINERALIZED BONE FIBER COMPOSITION FOR USE IN MINIMALLY INVASIVE SURGERY

A bone repair composition and methods thereof include bone fibers made from cortical bone in which a plurality of bone fibers are made into various implant shapes conducive to introduction into a patient through minimally invasive surgery. The bone fiber compositions may be in the form of a pellet or cylinder. A method includes producing the bone fiber graft efficiently with control of key parameters of cohesiveness, rehydration and swelling of the bone fiber graft. Another method includes introducing the bone fiber graft into the cannula efficiently. A method is also provided to allow introduction of a bone graft into a patient by placing the implant in a tube and expelling it through the action of a plunger. 1. A bone repair composition , comprising:a plurality of fibers cut from demineralized bone in a form of a pellet, the pellet having an outermost layer of bone fibers which are annealed.2. The bone repair composition of claim 1 , wherein the outermost layer of bone fibers are annealed by heating and/or dehydrothermal treatment.3. The bone repair composition of claim 1 , wherein the outermost layer of bone fibers are annealed by chemically combining a hydroxy group from a functional group of a collagen molecule of the outermost layer of bone fibers and a hydrogen ion from a functional group of another collagen molecule of the outermost layer of bone fibers.4. The bone repair composition of claim 1 , wherein the outermost layer of bone fibers are annealed by heating the bone fibers in a metallic mold.5. The bone repair composition of claim 4 , wherein the metallic mold is stainless steel.6. A method of making a bone repair composition for minimally invasive surgery claim 4 , comprising:demineralizing cortical bone to form demineralized bone;repeatedly cutting the demineralized bone to form a plurality of bone fibers; andadding the plurality of bone fibers to a mold to form a mold of bone fibers.7. The method of claim 6 , wherein the mold comprises an elongated ...

METHODS FOR DENSIFICATION AND STRUCTURAL ALIGNMENT OF BIOMINERALIZED MATERIAL

A method of vacuum densification and simultaneous alignment of mineral components formed inside biomineralized organoids includes providing a pressing die system that includes a push rod arranged within a sleeve, a sample chamber, and a semi-porous support plate equipped with a vacuum pump system. A hydrated biomineralized organoid sample, including a mineral component, is inserted into the sample chamber. The biomineralized organoid sample is mechanically compressed by exerting a force via the push rod so that a solid fraction of the biomineralized organoid sample is compressed while a portion of a liquid fraction passes through the semi-porous support plate, thereby leaving the biomineralized organoid sample in a partially dehydrated state. The portion of the liquid fraction that passes through the semi-porous support plate is removed via the vacuum pump system. Mechanical compression of the solid fraction and vacuum removal of the portion of the liquid fraction facilitates an increase in density of the mineral component and an increase in alignment of particles that comprise the mineral component. 1. A method of vacuum densification and simultaneous alignment of mineral components formed inside biomineralized organoids , the method comprising:providing a pressing die system that includes a push rod arranged within a sleeve, a sample chamber, and a semi-porous support plate equipped with a vacuum pump system;inserting a hydrated biomineralized organoid sample, including a mineral component, into the sample chamber;mechanically compressing the biomineralized organoid sample, by exerting a force via the push rod, so that a solid fraction of the biomineralized organoid sample is compressed while a portion of a liquid fraction passes through the semi-porous support plate, thereby leaving the biomineralized organoid sample in a partially dehydrated state; andremoving the portion of the liquid fraction that passes through the semi-porous support plate via the vacuum ...

Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation

The present invention relates to a composition comprising ex-vivo expanded adipose tissue derived stem cell (ASC) or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5,0×10−2,0×10ASCs/mL fat; for example 1,0×10−2,0×10and the use of ex-vivo expanded adipose tissue-derived stem cells or ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as an agent for cosmetic breast filling/augmentation or for facial filling/rejuvenation. 1. A composition comprising ex-vivo expanded adipose tissue-derived stem cell (ASC) enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5 ,0×10−2 ,0×10ASCs/mL fat.2. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as a breast filling agent.3. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells as a facial filling agent.4. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling.5. Use of ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts or ex-vivo expanded adipose tissue-derived stem cells for cosmetic facial filling.6. Cosmetic method of breast filling wherein adipose tissue-derived stem cell (ASC) enriched fat grafts is mixed with harvested fat tissue at a ratio of 5 ,0×10−2 ,0×10ASCs/mL fat , and wherein the fat is injected as aliquots or as strings with a long needle horizontally (parallel to the body) by inserting the needle from several points around the areola margin and at several points at the inframammary fold in variable directions and planes to achieve an even and natural appearing distribution of the graft.7. Cosmetic method of facial filling wherein expanded adipose tissue-derived stem cell (ASC) enriched fat grafts or ex-vivo expanded adipose tissue-derived stem ...

AMNIOTIC OR PLACENTAL PREPARATION AND DEVICE FOR OPHTHALMIC USE AS DRESSING TO ENHANCE HEALING

A biodegradable lens-shaped patch useful for healing and treatment of ocular conditions is disclosed. The patch is formed from a biodegradable carrier which carries amniotic extract and/or placental extract. The biodegradable carrier may be a collagen material. The lens-shaped patch may be shaped in the form of a conventional contact lens and s applied to a corneal surface to enhance healing of corneal injuries. After a certain period of time, the patch dissolves on its own and it need not be removed from the eye by a clinician. The degradation of the patch is controlled by the degree of cross-linking in the carrier material. 19-. (canceled)10. A lens-shaped patch that is applied to the cornea of an eye for the treatment of diseases and injuries to the cornea of an eye , comprising:a patch formed into the shape of a contact lens, wherein the lens-shaped patch is a uniform mixture of a biodegradable carrier material comprising collagen from a mammalian source and an active ingredient comprising an amniotic extract, a placental extract, or a combination thereof, wherein the lens-shaped patch has a convex exterior surface and a concave interior surface, wherein the interior surface of the lens-shaped patch conforms to the external surface of the cornea and the lens-shaped patch adheres to the cornea;wherein the collagen in the patch is cross-linked;wherein the lens-shaped patch dissolves while on the cornea; andwherein the lens-shaped patch does not contain a low water nonionic polymer, a high-water nonionic polymer, a low-water ionic polymer or a high-water ionic polymer.11. The lens-shaped patch of claim 10 , such that the active ingredient in the lens-shaped patch is in physical contact with the outer surface of the cornea.12. The lens-shaped patch of claim 10 , wherein the disease or injury to the eye is any of: dry eye syndrome claim 10 , corneal trauma claim 10 , corneal inflammation claim 10 , corneal burn injury claim 10 , or corneal ulcers.13. The lens-shaped ...

PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion which has been decellularized and at least one layer of chorion. Also described herein are methods for making and using the tissue grafts. 1. A laminated tissue graft comprising:a first membrane comprising modified decellularized amnion, wherein the modified amnion comprises an exposed basement membrane;a second membrane comprising cleaned and washed chorion membrane retaining a cellular component layered adjacent to the first membrane, said chorion membrane layered adjacent to said first membrane; andoptionally one or more additional membranes layered over the first or second membrane, wherein the one or more additional membranes is selected from the group consisting of amnion, decellularized amnion, chorion, decellularized chorion, allograft pericardium, allograft acellular dermis, amniotic membrane, Wharton's jelly, and combinations thereof;wherein the laminated tissue graft is dehydrated.2. The laminated tissue graft of claim 1 , wherein one side of the first membrane is a decellularized fibroblast layer.3. The laminated tissue graft of claim 1 , wherein one side of the first membrane is an exposed compact layer.4. The laminated tissue graft of claim 1 , wherein one side of the first membrane is the other side of the basement membrane claim 1 , wherein the other side of the basement membrane is exposed.5. (canceled)6. The laminated tissue graft of claim 1 , further comprising at least one component selected from the group consisting of a naturally occurring growth factor claim 1 , a platelet concentrate claim 1 , a bone marrow aspirate claim 1 , stem cells claim 1 , or an antibiotic. Human placental membrane (e.g. amniotic membrane or tissue) has been used for various types of reconstructive surgical procedures since the early 1900s. The membrane serves as a substrate material, more commonly referred to as a biological dressing or patch graft. ...

Solid Substrates for Promoting Cell and Tissue Growth

This invention provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a specific fluid uptake capacity value of at least 75%, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for promoting cell or tissue growth or restored function, which solid substrate is characterized by a substantial surface roughness (Ra) as measured by scanning electron microscopy or atomic force microscopy. The invention also provides for processes for selection of an optimized coral-based solid substrate for promoting cell or tissue growth or restored function and applications of the same. 1. A process for selection of an optimized marine organism skeletal derivative-based solid substrate for promoting cell or tissue growth or restored function , said process comprising:isolating or preparing a marine organism skeletal derivative-based solid material;establishing a specific fluid uptake capacity value of said marine organism skeletal derivative-based solid material, which specific fluid uptake capacity value is determined by establishing a spontaneous fluid uptake value divided by a total fluid uptake value; or establishing a contact angle value; andselecting a marine organism skeletal derivative-based solid material characterized by a specific fluid uptake capacity value of at least 75% or characterized by having a contact angle value of less than 60 degrees, when in contact with a fluid.2. The process of claim 1 , wherein said solid substrate is comprised substantially of a coral or coral-based derivative.3. The process of claim 1 , wherein said solid ...